# ID: svediakorp-gov329220
# author: 
# authorBorn: 
# pseudonym: 
# translator: 
# title: Riksdagens öppna data: Övrigt
# subtitle: Dp 22 medicinteknikdirektivet 9124 06
# originalTitle: 
# manuscriptDate: 
# originDate: 
# retrieveDate: 2020-06-08
# sourceDescription: Retrieved from Språkbanken's collection 'Riksdagens öppna data', collecting open data published by the Swedish government. The section referred to as 'Övrigt' contains miscellaneous documents not belonging to any of the other categories in 'Riksdagens öppna data'.
# genre: governmental
# subgenre: open data
# location: 
# language: sv
# languageVariety: 
# codeswitching: 
# originalLanguage: 
# manuscript: 
# manuscriptChapter: 
# manuscriptPages: 
# printer: 
# printedVolume: 
# printedIssue: 
# printedPages: 
# printedDate: 2006-05-31
# editor: 
# publisher: 
# digitisationMethod: 
# transcriptionPrinciples: 
# transcriber: 
# retrievedFrom: Språkbanken (https://spraakbanken.gu.se/)
# retrieveFormat: XML
# annotation: tokens, lemma, POS, morphology, syntax, named entities
# annotationMethod: automatic
# words: 1,725
# sentences: 68
# sentenceOrder: original
# URL: https://spraakbanken.gu.se/resurser/rd-ovr
# cite: 
# availability: CC-BY attribution (https://creativecommons.org/licenses/by/4.0/)


# sent_id = 1
# text =  THE EUROPEAN UNION Brussels, 12 May 2006 Interinstitutional File: 2005 / 0227 (COD) 9124 / / 06 LIMITE ECO 83 SAN 102 CODEC 450 NOTE from: General Secretariat to: Coreper / Council No.
1	_	_	THE	_	_	_	PM	_	PM.NOM	3	DT	_	_
2	_	_	EUROPEAN	_	_	_	PM	_	PM.NOM	1	HD	_	_
3	_	_	UNION	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	0	ROOT	_	_
4	_	_	Brussels	_	_	_	PM	ENAMEX.PPL.LOC	PM.NOM	3	ET	_	_
5	_	_	,	_	_	_	MID	_	MID	4	IK	_	_
6	_	_	12	_	_	_	RG	_	RG.NOM	7	AT	_	_
7	_	_	May	_	_	May	PM	ENAMEX.HUM.PRS	PM.NOM	10	DT	_	_
8	_	_	2006	_	_	_	RG	_	RG.NOM	10	DT	_	_
9	_	_	Interinstitutional	_	_	_	JJ	_	JJ.POS.UTR.SIN.IND.NOM	10	AT	_	_
10	_	_	File	_	_	file	NN	_	NN.UTR.SIN.IND.NOM	4	AN	_	_
11	_	_	:	_	_	_	MID	_	MID	10	IQ	_	_
12	_	_	2005	_	_	_	RG	_	RG.NOM	10	ET	_	_
13	_	_	/	_	_	_	MID	_	MID	12	ET	_	_
14	_	_	0227	_	_	_	RG	_	RG.NOM	13	ET	_	_
15	_	_	(	_	_	_	PAD	_	PAD	12	IR	_	_
16	_	_	COD	_	_	_	PM	_	PM.NOM	12	ET	_	_
17	_	_	)	_	_	_	PAD	_	PAD	16	JR	_	_
18	_	_	9124	_	_	_	RG	_	RG.NOM	16	ET	_	_
19	_	_	/	_	_	_	MID	_	MID	18	ET	_	_
20	_	_	/	_	_	_	MID	_	MID	19	IK	_	_
21	_	_	06	_	_	_	RG	_	RG.NOM	22	DT	_	_
22	_	_	LIMITE	_	_	_	PM	_	PM.NOM	19	ET	_	_
23	_	_	ECO	_	_	_	PM	_	PM.NOM	22	HD	_	_
24	_	_	83	_	_	_	RG	_	RG.NOM	22	ET	_	_
25	_	_	SAN	_	_	_	PM	ENAMEX.HUM.PRS	PM.NOM	24	ET	_	_
26	_	_	102	_	_	_	RG	_	RG.NOM	25	ET	_	_
27	_	_	CODEC	_	_	_	PM	_	PM.NOM	26	ET	_	_
28	_	_	450	_	_	_	RG	_	RG.NOM	29	DT	_	_
29	_	_	NOTE	_	_	_	PM	_	PM.NOM	27	HD	_	_
30	_	_	from	_	_	from	JJ	_	JJ.POS.UTR.SIN.IND.NOM	27	HD	_	_
31	_	_	:	_	_	_	MID	_	MID	27	IQ	_	_
32	_	_	General	_	_	_	PM	_	PM.NOM	27	AN	_	_
33	_	_	Secretariat	_	_	_	PM	ENAMEX.HUM.PRS	PM.NOM	32	HD	_	_
34	_	_	to	_	_	_	PM	_	PM.NOM	32	HD	_	_
35	_	_	:	_	_	_	MID	_	MID	32	IQ	_	_
36	_	_	Coreper	_	_	_	PM	_	PM.NOM	32	ET	_	_
37	_	_	/	_	_	_	MID	_	MID	36	HD	_	_
38	_	_	Council	_	_	_	PM	_	PM.NOM	36	HD	_	_
39	_	_	No	_	_	_	PM	_	PM.NOM	36	HD	_	_
40	_	_	.	_	_	_	MAD	_	MAD	3	IP	_	_

# sent_id = 2
# text =  Prev.
1	_	_	Prev	_	_	_	PM	_	PM.NOM	0	ROOT	_	_
2	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 3
# text =  doc.: DS 338 / 1 / 06 REV 1 ECO, SAN, CODEC No.
1	_	_	doc.	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
2	_	_	:	_	_	_	MID	_	MID	1	IQ	_	_
3	_	_	DS	_	_	_	PM	_	PM.NOM	1	ET	_	_
4	_	_	338	_	_	_	RG	_	RG.NOM	3	ET	_	_
5	_	_	/	_	_	_	MID	_	MID	6	IG	_	_
6	_	_	1	_	_	_	RG	_	RG.NOM	4	AN	_	_
7	_	_	/	_	_	_	MID	_	MID	6	ET	_	_
8	_	_	06	_	_	_	RG	_	RG.NOM	9	DT	_	_
9	_	_	REV	_	_	rev	NN	_	NN.AN	7	PA	_	_
10	_	_	1	_	_	_	RG	_	RG.NOM	14	CA	_	_
11	_	_	ECO	_	_	_	PM	_	PM.NOM	14	CJ	_	_
12	_	_	,	_	_	_	MID	_	MID	14	IK	_	_
13	_	_	SAN	_	_	_	PM	ENAMEX.HUM.PRS	PM.NOM	14	CJ	_	_
14	_	_	,	_	_	_	MID	_	MID	9	ET	_	_
15	_	_	CODEC	_	_	_	PM	_	PM.NOM	14	CJ	_	_
16	_	_	No	_	_	_	PM	_	PM.NOM	15	HD	_	_
17	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 4
# text =  Cion prop.
1	_	_	Cion	_	_	_	PM	_	PM.NOM	2	DT	_	_
2	_	_	prop	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	0	ROOT	_	_
3	_	_	.	_	_	_	MAD	_	MAD	2	IP	_	_

# sent_id = 5
# text = : 15023 / 05 ECO 147 SAN 192 CODEC 1100 Subject: Preparation of the Council (EPSCO) on 1 and 2 June 2006: Proposal for a Regulation of the European Parliament and of the Council on advanced therapy medicinal products and amending Directive 2001 / 83 / EC and Regulation (EC) No 726 / 2004 - Progress report 1.
1	_	_	:	_	_	_	MID	_	MID	2	IG	_	_
2	_	_	15023	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
3	_	_	/	_	_	_	MID	_	MID	2	ET	_	_
4	_	_	05	_	_	_	RG	_	RG.NOM	5	AT	_	_
5	_	_	ECO	_	_	_	PM	_	PM.NOM	3	ET	_	_
6	_	_	147	_	_	_	RG	_	RG.NOM	5	ET	_	_
7	_	_	SAN	_	_	_	PM	ENAMEX.HUM.PRS	PM.NOM	6	ET	_	_
8	_	_	192	_	_	_	RG	_	RG.NOM	7	ET	_	_
9	_	_	CODEC	_	_	_	PM	_	PM.NOM	8	ET	_	_
10	_	_	1100	_	_	_	RG	_	RG.NOM	11	JG	_	_
11	_	_	Subject	_	_	_	PM	_	PM.NOM	9	HD	_	_
12	_	_	:	_	_	_	MID	_	MID	9	IQ	_	_
13	_	_	Preparation	_	_	preparation	NN	_	NN.UTR.SIN.IND.NOM	14	DT	_	_
14	_	_	of	_	_	_	PM	_	PM.NOM	9	AN	_	_
15	_	_	the	_	_	_	PM	_	PM.NOM	14	HD	_	_
16	_	_	Council	_	_	_	PM	_	PM.NOM	14	HD	_	_
17	_	_	(	_	_	_	PAD	_	PAD	14	IR	_	_
18	_	_	EPSCO	_	_	_	PM	_	PM.NOM	14	HD	_	_
19	_	_	)	_	_	_	PAD	_	PAD	14	JR	_	_
20	_	_	on	_	_	_	UO	_	UO	14	ET	_	_
21	_	_	1	_	_	_	RG	_	RG.NOM	20	ET	_	_
22	_	_	and	_	_	_	UO	_	UO	24	DT	_	_
23	_	_	2	_	_	_	RG	_	RG.NOM	24	AT	_	_
24	_	_	June	_	_	_	PM	ENAMEX.HUM.PRS	PM.NOM	21	ET	_	_
25	_	_	2006	_	_	_	RG	_	RG.NOM	24	ET	_	_
26	_	_	:	_	_	_	MID	_	MID	25	IQ	_	_
27	_	_	Proposal	_	_	_	PM	_	PM.NOM	25	ET	_	_
28	_	_	for	_	_	_	UO	_	UO	27	PA	_	_
29	_	_	a	_	_	_	UO	_	UO	28	HD	_	_
30	_	_	Regulation	_	_	_	UO	_	UO	28	HD	_	_
31	_	_	of	_	_	_	UO	_	UO	28	HD	_	_
32	_	_	the	_	_	_	UO	ENAMEX.WMD.WRK	UO	28	HD	_	_
33	_	_	European	_	_	_	PM	ENAMEX.WMD.WRK	PM.NOM	28	ET	_	_
34	_	_	Parliament	_	_	_	PM	_	PM.NOM	33	HD	_	_
35	_	_	and	_	_	_	UO	_	UO	33	AN	_	_
36	_	_	of	_	_	_	UO	_	UO	35	HD	_	_
37	_	_	the	_	_	_	UO	ENAMEX.CRP.ORG	UO	35	HD	_	_
38	_	_	Council	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	35	ET	_	_
39	_	_	on	_	_	_	UO	ENAMEX.CRP.ORG	UO	38	AN	_	_
40	_	_	advanced	_	_	_	UO	ENAMEX.CRP.ORG	UO	39	HD	_	_
41	_	_	therapy	_	_	_	UO	_	UO	39	HD	_	_
42	_	_	medicinal	_	_	medicinal	NN	_	NN.UTR.SIN.IND.NOM	39	HD	_	_
43	_	_	products	_	_	_	UO	_	UO	39	HD	_	_
44	_	_	and	_	_	_	UO	_	UO	39	HD	_	_
45	_	_	amending	_	_	_	UO	_	UO	39	HD	_	_
46	_	_	Directive	_	_	_	PM	_	PM.NOM	39	OO	_	_
47	_	_	2001	_	_	_	RG	_	RG.NOM	46	ET	_	_
48	_	_	/	_	_	_	MID	_	MID	47	IK	_	_
49	_	_	83	_	_	_	RG	_	RG.NOM	47	RA	_	_
50	_	_	/	_	_	_	MID	_	MID	51	DT	_	_
51	_	_	EC	_	_	_	PM	_	PM.NOM	49	ET	_	_
52	_	_	and	_	_	_	UO	_	UO	51	ET	_	_
53	_	_	Regulation	_	_	_	UO	_	UO	52	HD	_	_
54	_	_	(	_	_	_	PAD	_	PAD	52	IR	_	_
55	_	_	EC	_	_	_	PM	_	PM.NOM	57	DT	_	_
56	_	_	)	_	_	_	PAD	_	PAD	55	JR	_	_
57	_	_	No	_	_	No	NN	_	NN.AN	52	AN	_	_
58	_	_	726	_	_	_	RG	_	RG.NOM	59	CJ	_	_
59	_	_	/	_	_	_	MID	_	MID	57	ET	_	_
60	_	_	2004	_	_	_	RG	_	RG.NOM	62	DT	_	_
61	_	_	-	_	_	_	MID	_	MID	62	DT	_	_
62	_	_	Progress	_	_	progress	NN	_	NN.UTR.SIN.IND.NOM	59	CJ	_	_
63	_	_	report	_	_	_	UO	_	UO	64	DT	_	_
64	_	_	1	_	_	_	RG	_	RG.NOM	57	AN	_	_
65	_	_	.	_	_	_	MAD	_	MAD	2	IP	_	_

# sent_id = 6
# text =  On 4 May 2006, the Working Party on Pharmaceuticals and Medical Devices examined a draft progress report prepared by the Presidency and the General Secretariat of the Council.
1	_	_	On	_	_	_	PM	_	PM.NOM	0	ROOT	_	_
2	_	_	4	_	_	_	RG	_	RG.NOM	3	AT	_	_
3	_	_	May	_	_	May	PM	ENAMEX.HUM.PRS	PM.NOM	1	ET	_	_
4	_	_	2006	_	_	_	RG	_	RG.NOM	3	ET	_	_
5	_	_	,	_	_	_	MID	_	MID	3	IK	_	_
6	_	_	the	_	_	_	PM	_	PM.NOM	8	DT	_	_
7	_	_	Working	_	_	_	PM	_	PM.NOM	6	HD	_	_
8	_	_	Party	_	_	party	NN	_	NN.NEU.SIN.IND.NOM	3	CJ	_	_
9	_	_	on	_	_	_	UO	_	UO	8	ET	_	_
10	_	_	Pharmaceuticals	_	_	_	PM	_	PM.NOM	9	UA	_	_
11	_	_	and	_	_	_	UO	_	UO	12	DT	_	_
12	_	_	Medical	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	10	HD	_	_
13	_	_	Devices	_	_	_	UO	_	UO	10	AN	_	_
14	_	_	examined	_	_	_	UO	_	UO	13	HD	_	_
15	_	_	a	_	_	_	UO	_	UO	13	HD	_	_
16	_	_	draft	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	17	DT	_	_
17	_	_	progress	_	_	progress	NN	_	NN.UTR.SIN.IND.NOM	13	OO	_	_
18	_	_	report	_	_	_	UO	_	UO	17	ET	_	_
19	_	_	prepared	_	_	_	UO	_	UO	18	AA	_	_
20	_	_	by	_	_	_	UO	_	UO	19	PA	_	_
21	_	_	the	_	_	_	UO	_	UO	20	HD	_	_
22	_	_	Presidency	_	_	_	UO	_	UO	20	HD	_	_
23	_	_	and	_	_	_	UO	_	UO	20	HD	_	_
24	_	_	the	_	_	_	UO	_	UO	20	HD	_	_
25	_	_	General	_	_	_	PM	_	PM.NOM	20	ET	_	_
26	_	_	Secretariat	_	_	_	PM	ENAMEX.HUM.PRS	PM.NOM	25	HD	_	_
27	_	_	of	_	_	_	PM	_	PM.NOM	25	HD	_	_
28	_	_	the	_	_	_	PM	_	PM.NOM	25	HD	_	_
29	_	_	Council	_	_	_	PM	_	PM.NOM	25	HD	_	_
30	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 7
# text =  The aim of the examination was to prepare for the Permanent Representatives Committee and the Council (EPSCO) a progress report that the Working Party could agree upon.
1	_	_	The	_	_	_	UO	_	UO	0	ROOT	_	_
2	_	_	aim	_	_	_	UO	_	UO	1	HD	_	_
3	_	_	of	_	_	_	UO	_	UO	2	AA	_	_
4	_	_	the	_	_	_	UO	_	UO	5	DT	_	_
5	_	_	examination	_	_	examination	NN	_	NN.UTR.SIN.IND.NOM	3	PA	_	_
6	_	_	was	_	_	_	UO	_	UO	5	ET	_	_
7	_	_	to	_	_	_	UO	_	UO	6	HD	_	_
8	_	_	prepare	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	7	SS	_	_
9	_	_	for	_	_	_	UO	_	UO	8	AN	_	_
10	_	_	the	_	_	_	UO	ENAMEX.CRP.ORG	UO	9	HD	_	_
11	_	_	Permanent	_	_	_	UO	ENAMEX.CRP.ORG	UO	10	HD	_	_
12	_	_	Representatives	_	_	representativ	JJ	ENAMEX.CRP.ORG	JJ.POS.MAS.SIN.DEF.GEN	13	DT	_	_
13	_	_	Committee	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	10	AN	_	_
14	_	_	and	_	_	_	PM	_	PM.NOM	13	HD	_	_
15	_	_	the	_	_	_	PM	_	PM.NOM	13	HD	_	_
16	_	_	Council	_	_	_	PM	_	PM.NOM	13	HD	_	_
17	_	_	(	_	_	_	PAD	_	PAD	13	IR	_	_
18	_	_	EPSCO	_	_	_	PM	_	PM.NOM	13	ET	_	_
19	_	_	)	_	_	_	PAD	_	PAD	18	JR	_	_
20	_	_	a	_	_	a	NN	_	NN.NEU.SIN.IND.NOM	21	DT	_	_
21	_	_	progress	_	_	progress	NN	_	NN.UTR.SIN.IND.NOM	18	OO	_	_
22	_	_	report	_	_	_	UO	_	UO	21	ET	_	_
23	_	_	that	_	_	_	UO	_	UO	22	HD	_	_
24	_	_	the	_	_	_	UO	_	UO	23	HD	_	_
25	_	_	Working	_	_	_	PM	_	PM.NOM	26	DT	_	_
26	_	_	Party	_	_	party	NN	_	NN.NEU.SIN.IND.NOM	23	TA	_	_
27	_	_	could	_	_	_	UO	_	UO	26	ET	_	_
28	_	_	agree	_	_	_	UO	_	UO	27	+F	_	_
29	_	_	upon	_	_	_	UO	_	UO	28	HD	_	_
30	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 8
# text =  Based on the outcome of this examination, the draft progress report was amended and distributed to delegations together with an invitation to comment in writing.
1	_	_	Based	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	0	ROOT	_	_
2	_	_	on	_	_	_	UO	_	UO	1	PA	_	_
3	_	_	the	_	_	_	UO	_	UO	2	HD	_	_
4	_	_	outcome	_	_	_	UO	_	UO	3	HD	_	_
5	_	_	of	_	_	_	UO	_	UO	3	HD	_	_
6	_	_	this	_	_	_	UO	_	UO	3	HD	_	_
7	_	_	examination	_	_	examination	NN	_	NN.UTR.SIN.IND.NOM	3	HD	_	_
8	_	_	,	_	_	_	MID	_	MID	2	IK	_	_
9	_	_	the	_	_	_	PM	_	PM.NOM	2	ET	_	_
10	_	_	draft	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	11	DT	_	_
11	_	_	progress	_	_	progress	NN	_	NN.UTR.SIN.IND.NOM	9	OO	_	_
12	_	_	report	_	_	_	UO	_	UO	11	ET	_	_
13	_	_	was	_	_	_	UO	_	UO	12	ET	_	_
14	_	_	amended	_	_	_	UO	_	UO	18	DT	_	_
15	_	_	and	_	_	_	UO	_	UO	14	HD	_	_
16	_	_	distributed	_	_	_	UO	_	UO	14	HD	_	_
17	_	_	to	_	_	_	UO	_	UO	14	HD	_	_
18	_	_	delegations	_	_	delegation	NN	_	NN.UTR.SIN.IND.GEN	13	UA	_	_
19	_	_	together	_	_	_	UO	_	UO	18	ET	_	_
20	_	_	with	_	_	_	UO	_	UO	19	AN	_	_
21	_	_	an	_	_	_	UO	_	UO	20	HD	_	_
22	_	_	invitation	_	_	invitation	NN	_	NN.UTR.SIN.IND.NOM	21	SS	_	_
23	_	_	to	_	_	_	UO	_	UO	22	AN	_	_
24	_	_	comment	_	_	_	UO	_	UO	23	+F	_	_
25	_	_	in	_	_	_	UO	_	UO	24	HD	_	_
26	_	_	writing	_	_	_	UO	_	UO	25	HD	_	_
27	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 9
# text =  2.
1	_	_	2	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
2	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 10
# text =  By 10 May 2006, eight delegations (DK, DE, ES, IT, PL, PT, SE, UK) had replied to this invitation.
1	_	_	By	_	_	by	NN	_	NN.UTR.SIN.IND.NOM	2	DT	_	_
2	_	_	10	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
3	_	_	May	_	_	May	PM	ENAMEX.HUM.PRS	PM.NOM	2	ET	_	_
4	_	_	2006	_	_	_	RG	_	RG.NOM	2	RA	_	_
5	_	_	,	_	_	_	MID	_	MID	4	IK	_	_
6	_	_	eight	_	_	_	UO	_	UO	7	DT	_	_
7	_	_	delegations	_	_	delegation	NN	_	NN.UTR.SIN.IND.GEN	3	SS	_	_
8	_	_	(	_	_	_	PAD	_	PAD	7	IR	_	_
9	_	_	DK	_	_	_	PM	_	PM.NOM	22	CJ	_	_
10	_	_	,	_	_	_	MID	_	MID	22	IK	_	_
11	_	_	DE	_	_	_	PM	_	PM.NOM	22	CJ	_	_
12	_	_	,	_	_	_	MID	_	MID	22	IK	_	_
13	_	_	ES	_	_	_	PM	_	PM.NOM	22	CJ	_	_
14	_	_	,	_	_	_	MID	_	MID	22	IK	_	_
15	_	_	IT	_	_	it|IT	NN	_	NN.AN	22	CJ	_	_
16	_	_	,	_	_	_	MID	_	MID	22	IK	_	_
17	_	_	PL	_	_	_	NN	_	NN.AN	22	CJ	_	_
18	_	_	,	_	_	_	MID	_	MID	22	IK	_	_
19	_	_	PT	_	_	_	PM	_	PM.NOM	22	CJ	_	_
20	_	_	,	_	_	_	MID	_	MID	22	IK	_	_
21	_	_	SE	_	_	_	PM	_	PM.NOM	22	CJ	_	_
22	_	_	,	_	_	_	MID	_	MID	29	DT	_	_
23	_	_	UK	_	_	_	PM	_	PM.NOM	22	CJ	_	_
24	_	_	)	_	_	_	PAD	_	PAD	22	JR	_	_
25	_	_	had	_	_	_	PM	_	PM.NOM	22	CJ	_	_
26	_	_	replied	_	_	_	UO	_	UO	29	DT	_	_
27	_	_	to	_	_	_	UO	_	UO	29	DT	_	_
28	_	_	this	_	_	_	UO	_	UO	29	DT	_	_
29	_	_	invitation	_	_	invitation	NN	_	NN.UTR.SIN.IND.NOM	7	AN	_	_
30	_	_	.	_	_	_	MAD	_	MAD	2	IP	_	_

# sent_id = 11
# text =  The draft progress report set out in the Annex to this Note has been further adjusted to take these written comments into account.
1	_	_	The	_	_	_	PM	_	PM.NOM	0	ROOT	_	_
2	_	_	draft	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	1	SS	_	_
3	_	_	progress	_	_	progress	NN	_	NN.UTR.SIN.IND.NOM	2	HD	_	_
4	_	_	report	_	_	_	JJ	_	JJ.POS.NEU.SIN.IND.NOM	2	HD	_	_
5	_	_	set	_	_	set	NN	_	NN.NEU.SIN.IND.NOM	2	HD	_	_
6	_	_	out	_	_	_	UO	_	UO	2	AN	_	_
7	_	_	in	_	_	_	UO	_	UO	6	AA	_	_
8	_	_	the	_	_	_	UO	_	UO	9	DT	_	_
9	_	_	Annex	_	_	annex	NN	ENAMEX.HUM.PRS	NN.NEU.SIN.IND.NOM	7	PA	_	_
10	_	_	to	_	_	_	UO	_	UO	9	ET	_	_
11	_	_	this	_	_	_	UO	_	UO	10	HD	_	_
12	_	_	Note	_	_	_	PM	_	PM.NOM	13	SS	_	_
13	_	_	has	_	_	ha	VB	_	VB.PRS.SFO	10	ET	_	_
14	_	_	been	_	_	_	NN	_	NN.UTR.SIN.DEF.NOM	13	OO	_	_
15	_	_	further	_	_	_	UO	_	UO	14	ET	_	_
16	_	_	adjusted	_	_	_	UO	_	UO	20	DT	_	_
17	_	_	to	_	_	_	UO	_	UO	16	HD	_	_
18	_	_	take	_	_	_	UO	_	UO	16	HD	_	_
19	_	_	these	_	_	_	UO	_	UO	16	HD	_	_
20	_	_	written	_	_	_	NN	_	NN.UTR.SIN.DEF.NOM	15	UA	_	_
21	_	_	comments	_	_	_	UO	_	UO	20	ET	_	_
22	_	_	into	_	_	_	PM	_	PM.NOM	21	HD	_	_
23	_	_	account	_	_	_	UO	_	UO	21	HD	_	_
24	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 12
# text =  3.
1	_	_	3	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
2	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 13
# text =  It was noted that the Spanish delegation reserved its position on point 8 of the draft progress report as well as on bullet points 1 and 4 under point 9.
1	_	_	It	_	_	_	UO	_	UO	0	ROOT	_	_
2	_	_	was	_	_	_	UO	_	UO	1	HD	_	_
3	_	_	noted	_	_	_	UO	_	UO	2	HD	_	_
4	_	_	that	_	_	_	UO	_	UO	2	HD	_	_
5	_	_	the	_	_	_	UO	_	UO	2	HD	_	_
6	_	_	Spanish	_	_	_	PM	_	PM.NOM	7	DT	_	_
7	_	_	delegation	_	_	delegation	NN	_	NN.UTR.SIN.IND.NOM	2	TA	_	_
8	_	_	reserved	_	_	_	UO	_	UO	7	ET	_	_
9	_	_	its	_	_	_	UO	_	UO	13	AA	_	_
10	_	_	position	_	_	_	UO	_	UO	9	HD	_	_
11	_	_	on	_	_	_	UO	_	UO	9	HD	_	_
12	_	_	point	_	_	_	UO	_	UO	9	HD	_	_
13	_	_	8	_	_	_	RG	_	RG.NOM	8	OO	_	_
14	_	_	of	_	_	_	UO	_	UO	13	ET	_	_
15	_	_	the	_	_	_	UO	_	UO	14	HD	_	_
16	_	_	draft	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	17	DT	_	_
17	_	_	progress	_	_	progress	NN	_	NN.UTR.SIN.IND.NOM	14	ET	_	_
18	_	_	report	_	_	_	UO	_	UO	17	ET	_	_
19	_	_	as	_	_	_	UO	_	UO	23	DT	_	_
20	_	_	well	_	_	_	JJ	_	JJ.POS.UTR.SIN.IND.NOM	23	DT	_	_
21	_	_	as	_	_	_	UO	_	UO	23	DT	_	_
22	_	_	on	_	_	_	UO	_	UO	21	HD	_	_
23	_	_	bullet	_	_	bull	NN	_	NN.NEU.SIN.DEF.NOM	24	SS	_	_
24	_	_	points	_	_	_	VB	_	VB.PRT.SFO	18	ET	_	_
25	_	_	1	_	_	_	RG	_	RG.NOM	26	AT	_	_
26	_	_	and	_	_	_	PM	_	PM.NOM	24	OO	_	_
27	_	_	4	_	_	_	RG	_	RG.NOM	24	TA	_	_
28	_	_	under	_	_	under	PP	_	PP	24	TA	_	_
29	_	_	point	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	30	DT	_	_
30	_	_	9	_	_	_	RG	_	RG.NOM	28	PA	_	_
31	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 14
# text =  The Permanent Representatives Committee is invited to - resolve the outstanding issues concerning points 8 and 9 in the Annex to this Note; - verify that delegations can agree to the report as redrafted and set out in the Annex to this Note; - agree to forward the progress report from the Working Party to the Council (EPSCO) for consideration at its session on 2 June 2006.
1	_	_	The	_	_	_	UO	_	UO	0	ROOT	_	_
2	_	_	Permanent	_	_	_	UO	ENAMEX.CRP.ORG	UO	4	DT	_	_
3	_	_	Representatives	_	_	representativ	JJ	ENAMEX.CRP.ORG	JJ.POS.MAS.SIN.DEF.GEN	4	AT	_	_
4	_	_	Committee	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	1	OO	_	_
5	_	_	is	_	_	_	UO	_	UO	4	ET	_	_
6	_	_	invited	_	_	_	UO	_	UO	5	HD	_	_
7	_	_	to	_	_	_	UO	_	UO	5	HD	_	_
8	_	_	-	_	_	_	MID	_	MID	5	IT	_	_
9	_	_	resolve	_	_	_	UO	_	UO	13	DT	_	_
10	_	_	the	_	_	_	UO	_	UO	9	HD	_	_
11	_	_	outstanding	_	_	_	UO	_	UO	9	HD	_	_
12	_	_	issues	_	_	_	UO	_	UO	9	HD	_	_
13	_	_	concerning	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	5	AN	_	_
14	_	_	points	_	_	_	UO	_	UO	15	DT	_	_
15	_	_	8	_	_	_	RG	_	RG.NOM	13	AN	_	_
16	_	_	and	_	_	_	UO	_	UO	15	PA	_	_
17	_	_	9	_	_	_	RG	_	RG.NOM	20	DT	_	_
18	_	_	in	_	_	_	UO	_	UO	20	DT	_	_
19	_	_	the	_	_	_	UO	_	UO	18	HD	_	_
20	_	_	Annex	_	_	annex	NN	ENAMEX.HUM.PRS	NN.NEU.SIN.IND.NOM	16	SS	_	_
21	_	_	to	_	_	_	UO	_	UO	20	ET	_	_
22	_	_	this	_	_	_	UO	_	UO	21	HD	_	_
23	_	_	Note	_	_	_	PM	_	PM.NOM	21	HD	_	_
24	_	_	;	_	_	_	MID	_	MID	21	IS	_	_
25	_	_	-	_	_	_	MID	_	MID	21	IT	_	_
26	_	_	verify	_	_	_	UO	_	UO	21	AN	_	_
27	_	_	that	_	_	_	UO	_	UO	26	HD	_	_
28	_	_	delegations	_	_	delegation	NN	_	NN.UTR.SIN.IND.GEN	27	SS	_	_
29	_	_	can	_	_	_	UO	_	UO	28	AN	_	_
30	_	_	agree	_	_	_	UO	_	UO	29	HD	_	_
31	_	_	to	_	_	_	UO	_	UO	30	HD	_	_
32	_	_	the	_	_	_	UO	_	UO	31	HD	_	_
33	_	_	report	_	_	_	UO	_	UO	31	HD	_	_
34	_	_	as	_	_	_	UO	_	UO	31	HD	_	_
35	_	_	redrafted	_	_	_	UO	_	UO	31	HD	_	_
36	_	_	and	_	_	_	UO	_	UO	31	HD	_	_
37	_	_	set	_	_	set	NN	_	NN.NEU.SIN.IND.NOM	31	HD	_	_
38	_	_	out	_	_	_	UO	_	UO	31	HD	_	_
39	_	_	in	_	_	_	UO	_	UO	31	HD	_	_
40	_	_	the	_	_	_	UO	_	UO	31	HD	_	_
41	_	_	Annex	_	_	annex	NN	ENAMEX.HUM.PRS	NN.NEU.SIN.IND.NOM	31	HD	_	_
42	_	_	to	_	_	_	UO	_	UO	31	HD	_	_
43	_	_	this	_	_	_	UO	_	UO	31	HD	_	_
44	_	_	Note	_	_	_	PM	_	PM.NOM	31	HD	_	_
45	_	_	;	_	_	_	MID	_	MID	30	IS	_	_
46	_	_	-	_	_	_	MID	_	MID	30	IT	_	_
47	_	_	agree	_	_	_	UO	_	UO	30	AN	_	_
48	_	_	to	_	_	_	UO	_	UO	47	HD	_	_
49	_	_	forward	_	_	forward	NN	_	NN.UTR.SIN.IND.NOM	50	DT	_	_
50	_	_	the	_	_	_	PM	_	PM.NOM	48	OO	_	_
51	_	_	progress	_	_	progress	NN	_	NN.UTR.SIN.IND.NOM	50	HD	_	_
52	_	_	report	_	_	_	UO	_	UO	50	ET	_	_
53	_	_	from	_	_	_	UO	_	UO	52	HD	_	_
54	_	_	the	_	_	_	UO	_	UO	52	HD	_	_
55	_	_	Working	_	_	_	PM	_	PM.NOM	56	DT	_	_
56	_	_	Party	_	_	party	NN	_	NN.NEU.SIN.IND.NOM	52	ET	_	_
57	_	_	to	_	_	_	UO	_	UO	56	ET	_	_
58	_	_	the	_	_	_	UO	_	UO	57	HD	_	_
59	_	_	Council	_	_	_	PM	_	PM.NOM	57	ET	_	_
60	_	_	(	_	_	_	PAD	_	PAD	59	IR	_	_
61	_	_	EPSCO	_	_	_	PM	_	PM.NOM	59	ET	_	_
62	_	_	)	_	_	_	PAD	_	PAD	61	JR	_	_
63	_	_	for	_	_	_	UO	_	UO	61	AN	_	_
64	_	_	consideration	_	_	_	UO	_	UO	63	HD	_	_
65	_	_	at	_	_	_	PM	_	PM.NOM	67	DT	_	_
66	_	_	its	_	_	_	UO	_	UO	67	DT	_	_
67	_	_	session	_	_	session	NN	_	NN.UTR.SIN.IND.NOM	63	ET	_	_
68	_	_	on	_	_	_	UO	_	UO	67	ET	_	_
69	_	_	2	_	_	_	RG	_	RG.NOM	70	AT	_	_
70	_	_	June	_	_	_	PM	ENAMEX.HUM.PRS	PM.NOM	68	ET	_	_
71	_	_	2006	_	_	_	RG	_	RG.NOM	70	ET	_	_
72	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 15
# text =  _ ANNEX Draft Progress Report from the Working Party on Pharmaceuticals and Medical Devices on the Proposal for a Regulation on advanced therapy medicinal products I. INTRODUCTION 1.
1	_	_	_	_	_	_	NN	_	NN.UTR.SIN.DEF.NOM	2	DT	_	_
2	_	_	ANNEX	_	_	_	PM	ENAMEX.HUM.PRS	PM.NOM	4	DT	_	_
3	_	_	Draft	_	_	_	PM	ENAMEX.HUM.PRS	PM.NOM	2	HD	_	_
4	_	_	Progress	_	_	progress	NN	ENAMEX.HUM.PRS	NN.UTR.SIN.IND.NOM	5	DT	_	_
5	_	_	Report	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	0	ROOT	_	_
6	_	_	from	_	_	_	UO	_	UO	5	ET	_	_
7	_	_	the	_	_	_	UO	_	UO	6	HD	_	_
8	_	_	Working	_	_	_	PM	_	PM.NOM	9	DT	_	_
9	_	_	Party	_	_	party	NN	_	NN.NEU.SIN.IND.NOM	6	PA	_	_
10	_	_	on	_	_	_	UO	_	UO	9	ET	_	_
11	_	_	Pharmaceuticals	_	_	_	PM	_	PM.NOM	10	OO	_	_
12	_	_	and	_	_	_	UO	_	UO	13	DT	_	_
13	_	_	Medical	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	11	HD	_	_
14	_	_	Devices	_	_	_	UO	_	UO	11	AN	_	_
15	_	_	on	_	_	_	UO	_	UO	14	HD	_	_
16	_	_	the	_	_	_	UO	_	UO	14	HD	_	_
17	_	_	Proposal	_	_	_	PM	_	PM.NOM	14	ET	_	_
18	_	_	for	_	_	_	UO	_	UO	17	AN	_	_
19	_	_	a	_	_	_	UO	_	UO	18	HD	_	_
20	_	_	Regulation	_	_	_	UO	_	UO	18	HD	_	_
21	_	_	on	_	_	_	UO	_	UO	18	HD	_	_
22	_	_	advanced	_	_	_	UO	_	UO	18	HD	_	_
23	_	_	therapy	_	_	_	UO	_	UO	18	HD	_	_
24	_	_	medicinal	_	_	medicinal	NN	_	NN.UTR.SIN.IND.NOM	18	HD	_	_
25	_	_	products	_	_	_	UO	_	UO	18	HD	_	_
26	_	_	I	_	_	_	UO	_	UO	18	HD	_	_
27	_	_	.	_	_	_	MAD	_	MAD	11	IP	_	_
28	_	_	INTRODUCTION	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	29	DT	_	_
29	_	_	1	_	_	_	RG	_	RG.NOM	11	ET	_	_
30	_	_	.	_	_	_	MAD	_	MAD	5	IP	_	_

# sent_id = 16
# text =  The Commission submitted its proposal for a Regulation on advanced therapy medicinal products to the Council and the European Parliament on 16 November 2005.
1	_	_	The	_	_	_	PM	_	PM.NOM	5	DT	_	_
2	_	_	Commission	_	_	_	PM	_	PM.NOM	1	HD	_	_
3	_	_	submitted	_	_	_	UO	_	UO	5	DT	_	_
4	_	_	its	_	_	_	UO	_	UO	3	HD	_	_
5	_	_	proposal	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	0	ROOT	_	_
6	_	_	for	_	_	_	UO	_	UO	5	AN	_	_
7	_	_	a	_	_	_	UO	_	UO	6	HD	_	_
8	_	_	Regulation	_	_	_	UO	_	UO	7	HD	_	_
9	_	_	on	_	_	_	UO	_	UO	7	HD	_	_
10	_	_	advanced	_	_	_	UO	_	UO	7	HD	_	_
11	_	_	therapy	_	_	_	UO	_	UO	7	HD	_	_
12	_	_	medicinal	_	_	medicinal	NN	_	NN.UTR.SIN.IND.NOM	7	HD	_	_
13	_	_	products	_	_	_	UO	_	UO	7	HD	_	_
14	_	_	to	_	_	_	UO	_	UO	7	HD	_	_
15	_	_	the	_	_	_	UO	_	UO	7	HD	_	_
16	_	_	Council	_	_	_	PM	_	PM.NOM	7	UA	_	_
17	_	_	and	_	_	_	UO	_	UO	16	PA	_	_
18	_	_	the	_	_	_	UO	ENAMEX.WMD.WRK	UO	17	HD	_	_
19	_	_	European	_	_	_	PM	ENAMEX.WMD.WRK	PM.NOM	23	DT	_	_
20	_	_	Parliament	_	_	_	PM	_	PM.NOM	19	HD	_	_
21	_	_	on	_	_	_	PM	_	PM.NOM	19	HD	_	_
22	_	_	16	_	_	_	RG	TIMEX.DAT.TME	RG.NOM	23	DT	_	_
23	_	_	November	_	_	november	NN	TIMEX.DAT.TME	NN.UTR.SIN.IND.NOM	24	DT	_	_
24	_	_	2005	_	_	_	RG	TIMEX.DAT.TME	RG.NOM	17	ET	_	_
25	_	_	.	_	_	_	MAD	_	MAD	5	IP	_	_

# sent_id = 17
# text =  The proposal is based on Article 95 of the Treaty.
1	_	_	The	_	_	_	PM	_	PM.NOM	0	ROOT	_	_
2	_	_	proposal	_	_	proposal	NN	_	NN.NEU.SIN.IND.NOM	1	SS	_	_
3	_	_	is	_	_	_	UO	_	UO	2	AN	_	_
4	_	_	based	_	_	_	UO	_	UO	7	AA	_	_
5	_	_	on	_	_	_	UO	_	UO	4	HD	_	_
6	_	_	Article	_	_	_	UO	_	UO	4	HD	_	_
7	_	_	95	_	_	_	RG	_	RG.NOM	3	OO	_	_
8	_	_	of	_	_	_	UO	_	UO	7	+F	_	_
9	_	_	the	_	_	_	UO	_	UO	8	HD	_	_
10	_	_	Treaty	_	_	_	PM	_	PM.NOM	8	HD	_	_
11	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 18
# text =  2.
1	_	_	2	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
2	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 19
# text =  The European Parliament is expected to give its first-reading opinion during the autumn 2006.
1	_	_	The	_	_	_	PM	ENAMEX.WMD.WRK	PM.NOM	7	SS	_	_
2	_	_	European	_	_	_	PM	ENAMEX.WMD.WRK	PM.NOM	1	HD	_	_
3	_	_	Parliament	_	_	_	PM	_	PM.NOM	1	HD	_	_
4	_	_	is	_	_	_	UO	_	UO	7	AA	_	_
5	_	_	expected	_	_	_	UO	_	UO	4	HD	_	_
6	_	_	to	_	_	_	UO	_	UO	4	HD	_	_
7	_	_	give	_	_	_	VB	_	VB.PRS.AKT	0	ROOT	_	_
8	_	_	its	_	_	_	UO	_	UO	7	AA	_	_
9	_	_	first-reading	_	_	_	UO	_	UO	8	HD	_	_
10	_	_	opinion	_	_	opinion	NN	_	NN.UTR.SIN.IND.NOM	11	DT	_	_
11	_	_	during	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	12	DT	_	_
12	_	_	the	_	_	_	PM	_	PM.NOM	14	AA	_	_
13	_	_	autumn	_	_	_	NN	_	NN.NEU.SIN.IND.NOM	12	HD	_	_
14	_	_	2006	_	_	_	RG	TIMEX.DAT.TME	RG.NOM	9	UA	_	_
15	_	_	.	_	_	_	MAD	_	MAD	7	IP	_	_

# sent_id = 20
# text =  3.
1	_	_	3	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
2	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 21
# text =  Under the Austrian Presidency, the Working Party on Pharmaceuticals and Medical devices has started a detailed examination of the proposal.
1	_	_	Under	_	_	PP	0	under	PP	_	RA	_	_
2	_	_	the	_	_	_	PM	_	PM.NOM	1	PA	_	_
3	_	_	Austrian	_	_	_	PM	_	PM.NOM	2	HD	_	_
4	_	_	Presidency	_	_	_	PM	_	PM.NOM	2	HD	_	_
5	_	_	,	_	_	_	MID	_	MID	2	IK	_	_
6	_	_	the	_	_	_	PM	_	PM.NOM	8	DT	_	_
7	_	_	Working	_	_	_	PM	_	PM.NOM	6	HD	_	_
8	_	_	Party	_	_	party	NN	_	NN.NEU.SIN.IND.NOM	2	AN	_	_
9	_	_	on	_	_	_	UO	_	UO	8	ET	_	_
10	_	_	Pharmaceuticals	_	_	_	PM	_	PM.NOM	14	SS	_	_
11	_	_	and	_	_	_	UO	_	UO	12	DT	_	_
12	_	_	Medical	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	10	HD	_	_
13	_	_	devices	_	_	_	UO	_	UO	10	HD	_	_
14	_	_	has	_	_	ha	VB	_	VB.PRS.SFO	9	ET	_	_
15	_	_	started	_	_	_	UO	_	UO	14	AA	_	_
16	_	_	a	_	_	_	UO	_	UO	15	HD	_	_
17	_	_	detailed	_	_	_	UO	_	UO	18	DT	_	_
18	_	_	examination	_	_	examination	NN	_	NN.UTR.SIN.IND.NOM	21	DT	_	_
19	_	_	of	_	_	_	UO	_	UO	21	DT	_	_
20	_	_	the	_	_	_	UO	_	UO	21	DT	_	_
21	_	_	proposal	_	_	proposal	NN	_	NN.UTR.SIN.IND.NOM	16	OP	_	_
22	_	_	.	_	_	MAD	0	_MAD	_	IP	_	_

# sent_id = 22
# text =  During eight meeting days, the Working Party has discussed all articles of and annexes to the proposal, in order to identify important issues for further consideration.
1	_	_	During	_	_	_	PM	_	PM.NOM	3	DT	_	_
2	_	_	eight	_	_	_	PM	_	PM.NOM	1	HD	_	_
3	_	_	meeting	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	0	ROOT	_	_
4	_	_	days	_	_	_	PM	_	PM.NOM	5	CJ	_	_
5	_	_	,	_	_	_	MID	_	MID	3	SS	_	_
6	_	_	the	_	_	_	PM	_	PM.NOM	5	CJ	_	_
7	_	_	Working	_	_	_	PM	_	PM.NOM	6	HD	_	_
8	_	_	Party	_	_	party	NN	_	NN.NEU.SIN.IND.NOM	9	SS	_	_
9	_	_	has	_	_	ha	VB	_	VB.PRS.SFO	3	ET	_	_
10	_	_	discussed	_	_	_	UO	_	UO	9	AA	_	_
11	_	_	all	_	_	_	UO	_	UO	10	HD	_	_
12	_	_	articles	_	_	_	UO	_	UO	11	HD	_	_
13	_	_	of	_	_	_	UO	_	UO	11	HD	_	_
14	_	_	and	_	_	_	UO	_	UO	11	HD	_	_
15	_	_	annexes	_	_	_	UO	_	UO	11	HD	_	_
16	_	_	to	_	_	_	UO	_	UO	11	HD	_	_
17	_	_	the	_	_	_	UO	_	UO	11	HD	_	_
18	_	_	proposal	_	_	proposal	NN	_	NN.UTR.SIN.IND.NOM	11	HD	_	_
19	_	_	,	_	_	_	MID	_	MID	3	IK	_	_
20	_	_	in	_	_	in	AB	_	AB	3	+F	_	_
21	_	_	order	_	_	order	NN	_	NN.UTR.SIN.IND.NOM	20	SS	_	_
22	_	_	to	_	_	_	UO	_	UO	21	AN	_	_
23	_	_	identify	_	_	_	UO	_	UO	22	AN	_	_
24	_	_	important	_	_	_	UO	_	UO	23	HD	_	_
25	_	_	issues	_	_	_	UO	_	UO	23	HD	_	_
26	_	_	for	_	_	_	UO	_	UO	23	HD	_	_
27	_	_	further	_	_	_	UO	_	UO	23	HD	_	_
28	_	_	consideration	_	_	_	UO	_	UO	23	HD	_	_
29	_	_	.	_	_	_	MAD	_	MAD	3	IP	_	_

# sent_id = 23
# text =  4.
1	_	_	4	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
2	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 24
# text =  At this stage several delegations have scrutiny reservations on certain articles and almost all delegations have linguistic reservations.
1	_	_	At	_	_	_	SN	_	SN	0	ROOT	_	_
2	_	_	this	_	_	_	UO	_	UO	1	PA	_	_
3	_	_	stage	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	5	DT	_	_
4	_	_	several	_	_	_	JJ	_	JJ.POS.UTR.SIN.IND.NOM	5	AT	_	_
5	_	_	delegations	_	_	delegation	NN	_	NN.UTR.SIN.IND.GEN	6	DT	_	_
6	_	_	have	_	_	_	PM	_	PM.NOM	8	DT	_	_
7	_	_	scrutiny	_	_	_	PM	_	PM.NOM	6	HD	_	_
8	_	_	reservations	_	_	reservation	NN	_	NN.UTR.SIN.IND.GEN	2	UA	_	_
9	_	_	on	_	_	_	UO	_	UO	8	ET	_	_
10	_	_	certain	_	_	_	UO	_	UO	9	AA	_	_
11	_	_	articles	_	_	_	UO	_	UO	10	PA	_	_
12	_	_	and	_	_	_	UO	_	UO	11	HD	_	_
13	_	_	almost	_	_	_	UO	_	UO	11	HD	_	_
14	_	_	all	_	_	_	UO	_	UO	11	HD	_	_
15	_	_	delegations	_	_	delegation	NN	_	NN.UTR.SIN.IND.GEN	16	DT	_	_
16	_	_	have	_	_	_	PM	_	PM.NOM	11	ET	_	_
17	_	_	linguistic	_	_	_	UO	_	UO	18	DT	_	_
18	_	_	reservations	_	_	reservation	NN	_	NN.UTR.SIN.IND.GEN	16	ET	_	_
19	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 25
# text =  The Danish, Maltese and United Kingdom delegations have parliamentary scrutiny reservations.
1	_	_	The	_	_	_	PM	_	PM.NOM	0	ROOT	_	_
2	_	_	Danish	_	_	_	PM	_	PM.NOM	1	ET	_	_
3	_	_	,	_	_	_	MID	_	MID	2	IK	_	_
4	_	_	Maltese	_	_	_	PM	_	PM.NOM	8	DT	_	_
5	_	_	and	_	_	_	PM	_	PM.NOM	4	HD	_	_
6	_	_	United	_	_	_	PM	ENAMEX.PPL.LOC	PM.NOM	4	HD	_	_
7	_	_	Kingdom	_	_	_	PM	ENAMEX.PPL.LOC	PM.NOM	4	HD	_	_
8	_	_	delegations	_	_	delegation	NN	_	NN.UTR.SIN.IND.GEN	9	DT	_	_
9	_	_	have	_	_	_	PM	_	PM.NOM	2	ET	_	_
10	_	_	parliamentary	_	_	_	UO	_	UO	12	DT	_	_
11	_	_	scrutiny	_	_	_	UO	_	UO	12	DT	_	_
12	_	_	reservations	_	_	reservation	NN	_	NN.UTR.SIN.IND.GEN	9	ET	_	_
13	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 26
# text =  5.
1	_	_	5	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
2	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 27
# text =  Delegations detailed comments on various articles, as recorded during the meetings or provided in writing, will be set out in footnotes to the proposed legal text in a separate document, the first version of which will be presented before the end of the Austrian Presidency.
1	_	_	Delegations	_	_	_	NN	_	NN.UTR.SIN.IND.GEN	0	ROOT	_	_
2	_	_	detailed	_	_	_	UO	_	UO	1	AN	_	_
3	_	_	comments	_	_	_	UO	_	UO	2	HD	_	_
4	_	_	on	_	_	_	UO	_	UO	3	HD	_	_
5	_	_	various	_	_	_	UO	_	UO	3	HD	_	_
6	_	_	articles	_	_	_	UO	_	UO	3	HD	_	_
7	_	_	,	_	_	_	MID	_	MID	3	IK	_	_
8	_	_	as	_	_	_	UO	_	UO	3	AN	_	_
9	_	_	recorded	_	_	_	UO	_	UO	8	HD	_	_
10	_	_	during	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	9	SS	_	_
11	_	_	the	_	_	_	UO	_	UO	10	AN	_	_
12	_	_	meetings	_	_	_	UO	_	UO	11	HD	_	_
13	_	_	or	_	_	_	UO	_	UO	12	HD	_	_
14	_	_	provided	_	_	_	UO	_	UO	12	HD	_	_
15	_	_	in	_	_	_	UO	_	UO	12	HD	_	_
16	_	_	writing	_	_	_	UO	_	UO	12	HD	_	_
17	_	_	,	_	_	_	MID	_	MID	11	IK	_	_
18	_	_	will	_	_	_	UO	_	UO	11	AA	_	_
19	_	_	be	_	_	_	UO	_	UO	20	DT	_	_
20	_	_	set	_	_	set	NN	_	NN.NEU.SIN.IND.NOM	23	SS	_	_
21	_	_	out	_	_	_	UO	_	UO	23	AA	_	_
22	_	_	in	_	_	_	UO	_	UO	21	HD	_	_
23	_	_	footnotes	_	_	_	VB	_	VB.PRT.SFO	18	ET	_	_
24	_	_	to	_	_	_	UO	_	UO	23	AA	_	_
25	_	_	the	_	_	_	UO	_	UO	24	AA	_	_
26	_	_	proposed	_	_	_	UO	_	UO	28	DT	_	_
27	_	_	legal	_	_	legal	JJ	_	JJ.POS.UTR.SIN.IND.NOM	28	AT	_	_
28	_	_	text	_	_	text	NN	_	NN.UTR.SIN.IND.NOM	25	PA	_	_
29	_	_	in	_	_	_	UO	_	UO	28	ET	_	_
30	_	_	a	_	_	_	UO	_	UO	32	DT	_	_
31	_	_	separate	_	_	separat	JJ	_	JJ.POS.MAS.SIN.DEF.NOM	32	AT	_	_
32	_	_	document	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	29	PA	_	_
33	_	_	,	_	_	_	MID	_	MID	32	IK	_	_
34	_	_	the	_	_	_	PM	_	PM.NOM	42	SS	_	_
35	_	_	first	_	_	_	NN	_	NN.NEU.SIN.DEF.NOM	34	HD	_	_
36	_	_	version	_	_	_	UO	_	UO	42	AA	_	_
37	_	_	of	_	_	_	UO	_	UO	36	HD	_	_
38	_	_	which	_	_	_	UO	_	UO	36	HD	_	_
39	_	_	will	_	_	_	UO	_	UO	36	HD	_	_
40	_	_	be	_	_	_	UO	_	UO	36	HD	_	_
41	_	_	presented	_	_	_	UO	_	UO	36	HD	_	_
42	_	_	before	_	_	befara	VB	_	VB.PRT.AKT	32	ET	_	_
43	_	_	the	_	_	_	UO	_	UO	42	AA	_	_
44	_	_	end	_	_	_	UO	_	UO	43	AA	_	_
45	_	_	of	_	_	_	UO	_	UO	44	PA	_	_
46	_	_	the	_	_	_	UO	_	UO	45	HD	_	_
47	_	_	Austrian	_	_	_	PM	_	PM.NOM	45	ET	_	_
48	_	_	Presidency	_	_	_	PM	_	PM.NOM	47	HD	_	_
49	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 28
# text =  This document is intended to provide a basis for the continued examination of the proposal.
1	_	_	This	_	_	_	PM	_	PM.NOM	0	ROOT	_	_
2	_	_	document	_	_	_	NN	_	NN.NEU.SIN.IND.NOM	1	OO	_	_
3	_	_	is	_	_	_	UO	_	UO	2	ET	_	_
4	_	_	intended	_	_	_	UO	_	UO	15	DT	_	_
5	_	_	to	_	_	_	UO	_	UO	4	HD	_	_
6	_	_	provide	_	_	_	UO	_	UO	4	HD	_	_
7	_	_	a	_	_	_	UO	_	UO	4	HD	_	_
8	_	_	basis	_	_	basis	NN	_	NN.UTR.SIN.IND.NOM	4	HD	_	_
9	_	_	for	_	_	_	UO	_	UO	4	HD	_	_
10	_	_	the	_	_	_	UO	_	UO	4	HD	_	_
11	_	_	continued	_	_	_	UO	_	UO	4	HD	_	_
12	_	_	examination	_	_	examination	NN	_	NN.UTR.SIN.IND.NOM	4	HD	_	_
13	_	_	of	_	_	_	UO	_	UO	4	HD	_	_
14	_	_	the	_	_	_	UO	_	UO	15	DT	_	_
15	_	_	proposal	_	_	proposal	NN	_	NN.UTR.SIN.IND.NOM	3	UA	_	_
16	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 29
# text =  II.
1	_	_	II	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
2	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 30
# text =  STATE OF PLAY 6.
1	_	_	STATE	_	_	_	PM	_	PM.NOM	4	AA	_	_
2	_	_	OF	_	_	_	PM	_	PM.NOM	1	HD	_	_
3	_	_	PLAY	_	_	_	PM	_	PM.NOM	1	HD	_	_
4	_	_	6	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
5	_	_	.	_	_	_	MAD	_	MAD	4	IP	_	_

# sent_id = 31
# text =  In general, delegations have welcomed the proposal as an important legislative initiative aiming at creating a single, integrated legal framework that fully takes into account the scientific and technical characteristics of the three fields of advanced therapies, namely gene therapy, somatic cell therapy and tissue-engineering, as well as the specificities of the economic operators concerned, thereby facilitating the free movement of advanced therapy products in the Community, and improving patients access to these innovative therapies.
1	_	_	In	_	_	_	AB	_	AB	0	ROOT	_	_
2	_	_	general	_	_	general	NN	_	NN.UTR.SIN.IND.NOM	1	SS	_	_
3	_	_	,	_	_	_	MID	_	MID	2	IK	_	_
4	_	_	delegations	_	_	delegation	NN	_	NN.UTR.SIN.IND.GEN	5	DT	_	_
5	_	_	have	_	_	_	PM	_	PM.NOM	2	AN	_	_
6	_	_	welcomed	_	_	_	UO	_	UO	5	ET	_	_
7	_	_	the	_	_	_	UO	_	UO	6	HD	_	_
8	_	_	proposal	_	_	proposal	NN	_	NN.UTR.SIN.IND.NOM	6	HD	_	_
9	_	_	as	_	_	_	UO	_	UO	6	HD	_	_
10	_	_	an	_	_	_	UO	_	UO	6	HD	_	_
11	_	_	important	_	_	_	UO	_	UO	6	HD	_	_
12	_	_	legislative	_	_	legislativ	JJ	_	JJ.POS.MAS.SIN.DEF.NOM	16	AT	_	_
13	_	_	initiative	_	_	_	JJ	_	JJ.POS.MAS.SIN.DEF.NOM	14	DT	_	_
14	_	_	aiming	_	_	_	PM	_	PM.NOM	16	DT	_	_
15	_	_	at	_	_	_	PM	_	PM.NOM	14	HD	_	_
16	_	_	creating	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	6	OO	_	_
17	_	_	a	_	_	_	UO	_	UO	16	ET	_	_
18	_	_	single	_	_	_	UO	_	UO	17	HD	_	_
19	_	_	,	_	_	_	MID	_	MID	17	IK	_	_
20	_	_	integrated	_	_	_	UO	_	UO	17	AN	_	_
21	_	_	legal	_	_	legal	JJ	_	JJ.POS.UTR.SIN.IND.NOM	26	AT	_	_
22	_	_	framework	_	_	_	UO	_	UO	26	DT	_	_
23	_	_	that	_	_	_	UO	_	UO	22	HD	_	_
24	_	_	fully	_	_	_	UO	_	UO	22	HD	_	_
25	_	_	takes	_	_	_	UO	_	UO	22	HD	_	_
26	_	_	into	_	_	_	PM	_	PM.NOM	20	ET	_	_
27	_	_	account	_	_	_	UO	_	UO	26	ET	_	_
28	_	_	the	_	_	_	UO	_	UO	27	HD	_	_
29	_	_	scientific	_	_	_	UO	_	UO	27	HD	_	_
30	_	_	and	_	_	_	UO	_	UO	27	HD	_	_
31	_	_	technical	_	_	_	UO	_	UO	27	HD	_	_
32	_	_	characteristics	_	_	_	UO	_	UO	27	HD	_	_
33	_	_	of	_	_	_	UO	_	UO	27	HD	_	_
34	_	_	the	_	_	_	UO	_	UO	27	HD	_	_
35	_	_	three	_	_	_	UO	_	UO	27	HD	_	_
36	_	_	fields	_	_	field	NN	_	NN.UTR.SIN.IND.GEN	27	HD	_	_
37	_	_	of	_	_	_	UO	_	UO	27	HD	_	_
38	_	_	advanced	_	_	_	UO	_	UO	27	HD	_	_
39	_	_	therapies	_	_	_	UO	_	UO	27	HD	_	_
40	_	_	,	_	_	_	MID	_	MID	27	IK	_	_
41	_	_	namely	_	_	_	UO	_	UO	27	AN	_	_
42	_	_	gene	_	_	gen	JJ	_	JJ.POS.MAS.SIN.DEF.NOM	41	PT	_	_
43	_	_	therapy	_	_	_	UO	_	UO	42	AN	_	_
44	_	_	,	_	_	_	MID	_	MID	43	IK	_	_
45	_	_	somatic	_	_	_	UO	_	UO	43	AN	_	_
46	_	_	cell	_	_	cell	NN	_	NN.UTR.SIN.IND.NOM	45	SS	_	_
47	_	_	therapy	_	_	_	UO	_	UO	46	AN	_	_
48	_	_	and	_	_	_	UO	_	UO	47	HD	_	_
49	_	_	tissue-engineering	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	48	SS	_	_
50	_	_	,	_	_	_	MID	_	MID	49	IK	_	_
51	_	_	as	_	_	_	PM	_	PM.NOM	49	ET	_	_
52	_	_	well	_	_	_	NN	_	NN.NEU.SIN.IND.NOM	51	HD	_	_
53	_	_	as	_	_	_	UO	_	UO	49	AN	_	_
54	_	_	the	_	_	_	UO	_	UO	53	HD	_	_
55	_	_	specificities	_	_	_	UO	_	UO	54	HD	_	_
56	_	_	of	_	_	_	UO	_	UO	54	HD	_	_
57	_	_	the	_	_	_	UO	_	UO	54	HD	_	_
58	_	_	economic	_	_	_	UO	_	UO	54	HD	_	_
59	_	_	operators	_	_	operator	NN	_	NN.UTR.SIN.IND.GEN	54	HD	_	_
60	_	_	concerned	_	_	concerned	NN	_	NN.UTR.SIN.IND.NOM	54	HD	_	_
61	_	_	,	_	_	_	MID	_	MID	49	IK	_	_
62	_	_	thereby	_	_	thereby	NN	_	NN.UTR.SIN.IND.NOM	63	DT	_	_
63	_	_	facilitating	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	49	AN	_	_
64	_	_	the	_	_	_	UO	_	UO	63	ET	_	_
65	_	_	free	_	_	_	UO	_	UO	64	HD	_	_
66	_	_	movement	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	65	SS	_	_
67	_	_	of	_	_	_	UO	_	UO	66	AN	_	_
68	_	_	advanced	_	_	_	UO	_	UO	67	HD	_	_
69	_	_	therapy	_	_	_	UO	_	UO	68	HD	_	_
70	_	_	products	_	_	_	UO	_	UO	68	HD	_	_
71	_	_	in	_	_	_	UO	_	UO	68	HD	_	_
72	_	_	the	_	_	_	UO	_	UO	68	HD	_	_
73	_	_	Community	_	_	_	PM	_	PM.NOM	74	CJ	_	_
74	_	_	,	_	_	_	MID	_	MID	77	DT	_	_
75	_	_	and	_	_	_	PM	_	PM.NOM	74	CJ	_	_
76	_	_	improving	_	_	_	JJ	_	JJ.POS.UTR.SIN.IND.NOM	77	AT	_	_
77	_	_	patients	_	_	patient	NN	_	NN.UTR.SIN.IND.GEN	78	DT	_	_
78	_	_	access	_	_	access	NN	_	NN.UTR.SIN.IND.NOM	68	OO	_	_
79	_	_	to	_	_	_	UO	_	UO	78	ET	_	_
80	_	_	these	_	_	_	UO	_	UO	79	HD	_	_
81	_	_	innovative	_	_	innovativ	JJ	_	JJ.POS.MAS.SIN.DEF.NOM	80	PT	_	_
82	_	_	therapies	_	_	_	UO	_	UO	81	HD	_	_
83	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 32
# text =  7.
1	_	_	7	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
2	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 33
# text =  There is general support in the Working Party that gene therapy, somatic cell therapy and tissue engineered products, both of human and animal origin, should be regulated together in a single regulation on advanced therapy medicinal products.
1	_	_	There	_	_	_	UO	_	UO	0	ROOT	_	_
2	_	_	is	_	_	_	UO	_	UO	3	DT	_	_
3	_	_	general	_	_	general	NN	_	NN.UTR.SIN.IND.NOM	1	SS	_	_
4	_	_	support	_	_	support	NN	_	NN.UTR.SIN.IND.NOM	8	DT	_	_
5	_	_	in	_	_	in	AB	_	AB	8	CA	_	_
6	_	_	the	_	_	_	PM	_	PM.NOM	8	DT	_	_
7	_	_	Working	_	_	_	PM	_	PM.NOM	6	HD	_	_
8	_	_	Party	_	_	party	NN	_	NN.NEU.SIN.IND.NOM	3	OO	_	_
9	_	_	that	_	_	_	UO	_	UO	8	ET	_	_
10	_	_	gene	_	_	gen	JJ	_	JJ.POS.MAS.SIN.DEF.NOM	9	PT	_	_
11	_	_	therapy	_	_	_	UO	_	UO	10	AN	_	_
12	_	_	,	_	_	_	MID	_	MID	11	IK	_	_
13	_	_	somatic	_	_	_	UO	_	UO	11	AN	_	_
14	_	_	cell	_	_	cell	NN	_	NN.UTR.SIN.IND.NOM	13	SS	_	_
15	_	_	therapy	_	_	_	UO	_	UO	14	AN	_	_
16	_	_	and	_	_	_	UO	_	UO	15	HD	_	_
17	_	_	tissue	_	_	_	UO	_	UO	16	HD	_	_
18	_	_	engineered	_	_	_	UO	_	UO	16	HD	_	_
19	_	_	products	_	_	_	UO	_	UO	16	HD	_	_
20	_	_	,	_	_	_	MID	_	MID	16	IK	_	_
21	_	_	both	_	_	_	UO	_	UO	16	AA	_	_
22	_	_	of	_	_	_	UO	_	UO	21	HD	_	_
23	_	_	human	_	_	human	JJ	_	JJ.POS.UTR.SIN.IND.NOM	26	DT	_	_
24	_	_	and	_	_	_	UO	_	UO	26	DT	_	_
25	_	_	animal	_	_	animal	JJ	_	JJ.POS.UTR.SIN.IND.NOM	26	AT	_	_
26	_	_	origin	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	21	TA	_	_
27	_	_	,	_	_	_	MID	_	MID	26	IK	_	_
28	_	_	should	_	_	_	UO	_	UO	26	AN	_	_
29	_	_	be	_	_	_	UO	_	UO	28	AN	_	_
30	_	_	regulated	_	_	_	UO	_	UO	29	HD	_	_
31	_	_	together	_	_	_	UO	_	UO	29	HD	_	_
32	_	_	in	_	_	_	UO	_	UO	29	HD	_	_
33	_	_	a	_	_	_	UO	_	UO	29	HD	_	_
34	_	_	single	_	_	_	UO	_	UO	29	HD	_	_
35	_	_	regulation	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	29	HD	_	_
36	_	_	on	_	_	_	UO	_	UO	29	HD	_	_
37	_	_	advanced	_	_	_	UO	_	UO	29	HD	_	_
38	_	_	therapy	_	_	_	UO	_	UO	29	HD	_	_
39	_	_	medicinal	_	_	medicinal	NN	_	NN.UTR.SIN.IND.NOM	29	HD	_	_
40	_	_	products	_	_	_	UO	_	UO	29	HD	_	_
41	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 34
# text =  There is also strong support for the principle that this regulation should be without prejudice to national legislation prohibiting or restricting, on ethical grounds, the use of certain cells, tissues and advanced therapy medicinal products derived from them.
1	_	_	There	_	_	_	UO	_	UO	0	ROOT	_	_
2	_	_	is	_	_	_	UO	_	UO	1	AA	_	_
3	_	_	also	_	_	_	UO	_	UO	5	DT	_	_
4	_	_	strong	_	_	strong	JJ	_	JJ.POS.UTR.SIN.IND.NOM	5	AT	_	_
5	_	_	support	_	_	support	NN	_	NN.UTR.SIN.IND.NOM	2	PA	_	_
6	_	_	for	_	_	_	UO	_	UO	5	ET	_	_
7	_	_	the	_	_	_	UO	_	UO	11	DT	_	_
8	_	_	principle	_	_	_	UO	_	UO	7	HD	_	_
9	_	_	that	_	_	_	UO	_	UO	7	HD	_	_
10	_	_	this	_	_	_	UO	_	UO	7	HD	_	_
11	_	_	regulation	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	6	UA	_	_
12	_	_	should	_	_	_	UO	_	UO	11	ET	_	_
13	_	_	be	_	_	_	UO	_	UO	12	HD	_	_
14	_	_	without	_	_	_	UO	_	UO	13	HD	_	_
15	_	_	prejudice	_	_	_	UO	_	UO	13	HD	_	_
16	_	_	to	_	_	_	UO	_	UO	13	HD	_	_
17	_	_	national	_	_	_	UO	_	UO	13	HD	_	_
18	_	_	legislation	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	13	HD	_	_
19	_	_	prohibiting	_	_	_	UO	_	UO	13	HD	_	_
20	_	_	or	_	_	_	UO	_	UO	13	HD	_	_
21	_	_	restricting	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	13	HD	_	_
22	_	_	,	_	_	_	MID	_	MID	12	IK	_	_
23	_	_	on	_	_	_	UO	_	UO	12	AA	_	_
24	_	_	ethical	_	_	_	UO	_	UO	23	HD	_	_
25	_	_	grounds	_	_	_	UO	_	UO	23	HD	_	_
26	_	_	,	_	_	_	MID	_	MID	23	IK	_	_
27	_	_	the	_	_	_	UO	_	UO	31	DT	_	_
28	_	_	use	_	_	_	UO	_	UO	27	HD	_	_
29	_	_	of	_	_	_	UO	_	UO	27	HD	_	_
30	_	_	certain	_	_	_	UO	_	UO	27	HD	_	_
31	_	_	cells	_	_	cell	NN	_	NN.UTR.SIN.IND.GEN	23	AN	_	_
32	_	_	,	_	_	_	MID	_	MID	31	IK	_	_
33	_	_	tissues	_	_	_	UO	_	UO	31	AN	_	_
34	_	_	and	_	_	_	UO	_	UO	33	HD	_	_
35	_	_	advanced	_	_	_	UO	_	UO	34	AN	_	_
36	_	_	therapy	_	_	_	UO	_	UO	35	HD	_	_
37	_	_	medicinal	_	_	medicinal	NN	_	NN.UTR.SIN.IND.NOM	36	SS	_	_
38	_	_	products	_	_	_	UO	_	UO	37	AN	_	_
39	_	_	derived	_	_	_	UO	_	UO	38	+F	_	_
40	_	_	from	_	_	_	UO	_	UO	39	HD	_	_
41	_	_	them	_	_	_	UO	_	UO	40	HD	_	_
42	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 35
# text =  8.
1	_	_	8	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
2	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 36
# text =  The Working Party, in its first examination, reached broad agreement that advanced therapy products should be evaluated through a centralised procedure involving the European Medicines Agency (EMEA), the evaluation leading to a Community marketing authorisation; a Committee for Advanced Therapies (CAT) should be established within the EMEA with the task - among others - to advise the Agencys Committee for Medicinal Products for Human Use (CHMP) on the assessment of all advanced therapy medicinal products; some of the members of CAT should be elected among the members of the CHMP, CAT should also have members representing clinicians and patients associations.
1	_	_	The	_	_	_	PM	_	PM.NOM	03	DT	_	_
2	_	_	Working	_	_	_	PM	_	PM.NOM	01	HD	_	_
3	_	_	Party	_	_	_	NN	_	NN.NEU.SIN.IND.NOM	0	ROOT	_	_
4	_	_	,	_	_	_	MID	_	MID	03	IK	_	_
5	_	_	in	_	_	_	UO	_	UO	03	AN	_	_
6	_	_	its	_	_	_	UO	_	UO	05	HD	_	_
7	_	_	first	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	08	DT	_	_
8	_	_	examination	_	_	examination	NN	_	NN.UTR.SIN.IND.NOM	06	SS	_	_
9	_	_	,	_	_	_	MID	_	MID	08	IK	_	_
10	_	_	reached	_	_	_	PC	_	PC.PRF.UTR.SIN.IND.NOM	12	AT	_	_
11	_	_	broad	_	_	broa	PC	_	PC.PRF.UTR.SIN.IND.NOM	12	AT	_	_
12	_	_	agreement	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	08	AN	_	_
13	_	_	that	_	_	_	UO	_	UO	12	AN	_	_
14	_	_	advanced	_	_	_	UO	_	UO	13	HD	_	_
15	_	_	therapy	_	_	_	UO	_	UO	14	HD	_	_
16	_	_	products	_	_	_	UO	_	UO	14	HD	_	_
17	_	_	should	_	_	_	UO	_	UO	14	HD	_	_
18	_	_	be	_	_	_	UO	_	UO	14	HD	_	_
19	_	_	evaluated	_	_	_	UO	_	UO	14	HD	_	_
20	_	_	through	_	_	_	UO	_	UO	14	HD	_	_
21	_	_	a	_	_	_	UO	_	UO	14	HD	_	_
22	_	_	centralised	_	_	_	UO	_	UO	14	HD	_	_
23	_	_	procedure	_	_	_	UO	_	UO	14	HD	_	_
24	_	_	involving	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	14	HD	_	_
25	_	_	the	_	_	_	PM	ENAMEX.WMD.WRK	PM.NOM	14	AN	_	_
26	_	_	European	_	_	_	PM	ENAMEX.WMD.WRK	PM.NOM	25	HD	_	_
27	_	_	Medicines	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	25	HD	_	_
28	_	_	Agency	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	25	HD	_	_
29	_	_	(	_	_	_	PAD	_	PAD	25	IR	_	_
30	_	_	EMEA	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	25	AN	_	_
31	_	_	)	_	_	_	PAD	_	PAD	25	JR	_	_
32	_	_	,	_	_	_	MID	_	MID	13	IK	_	_
33	_	_	the	_	_	_	UO	_	UO	13	AA	_	_
34	_	_	evaluation	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	33	SS	_	_
35	_	_	leading	_	_	_	UO	_	UO	34	ET	_	_
36	_	_	to	_	_	_	UO	_	UO	40	DT	_	_
37	_	_	a	_	_	_	UO	_	UO	36	HD	_	_
38	_	_	Community	_	_	_	PM	_	PM.NOM	39	DT	_	_
39	_	_	marketing	_	_	marketing	NN	_	NN.UTR.SIN.IND.NOM	40	DT	_	_
40	_	_	authorisation	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	35	UA	_	_
41	_	_	;	_	_	_	MID	_	MID	40	IQ	_	_
42	_	_	a	_	_	_	PM	_	PM.NOM	40	AN	_	_
43	_	_	Committee	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	42	HD	_	_
44	_	_	for	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	42	HD	_	_
45	_	_	Advanced	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	42	HD	_	_
46	_	_	Therapies	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	42	HD	_	_
47	_	_	(	_	_	_	PAD	_	PAD	42	IR	_	_
48	_	_	CAT	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	42	ET	_	_
49	_	_	)	_	_	_	PAD	_	PAD	48	JR	_	_
50	_	_	should	_	_	_	UO	_	UO	48	AN	_	_
51	_	_	be	_	_	_	UO	_	UO	50	HD	_	_
52	_	_	established	_	_	_	UO	_	UO	50	HD	_	_
53	_	_	within	_	_	_	UO	_	UO	50	HD	_	_
54	_	_	the	_	_	_	UO	_	UO	50	HD	_	_
55	_	_	EMEA	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	71	SS	_	_
56	_	_	with	_	_	_	UO	_	UO	55	AA	_	_
57	_	_	the	_	_	_	UO	_	UO	56	HD	_	_
58	_	_	task	_	_	_	UO	_	UO	56	HD	_	_
59	_	_	-	_	_	_	MID	_	MID	56	IT	_	_
60	_	_	among	_	_	_	PM	_	PM.NOM	61	DT	_	_
61	_	_	others	_	_	_	UO	_	UO	56	PA	_	_
62	_	_	-	_	_	_	MID	_	MID	61	IT	_	_
63	_	_	to	_	_	_	UO	_	UO	61	AA	_	_
64	_	_	advise	_	_	_	UO	_	UO	63	PA	_	_
65	_	_	the	_	_	_	UO	ENAMEX.CRP.ORG	UO	64	HD	_	_
66	_	_	Agencys	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	64	ET	_	_
67	_	_	Committee	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	66	HD	_	_
68	_	_	for	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	66	HD	_	_
69	_	_	Medicinal	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	66	HD	_	_
70	_	_	Products	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	66	HD	_	_
71	_	_	for	_	_	fara	VB	_	VB.PRT.AKT	50	ET	_	_
72	_	_	Human	_	_	_	UO	_	UO	71	OO	_	_
73	_	_	Use	_	_	_	UO	_	UO	72	HD	_	_
74	_	_	(	_	_	_	PAD	_	PAD	72	IR	_	_
75	_	_	CHMP	_	_	_	PM	_	PM.NOM	72	AN	_	_
76	_	_	)	_	_	_	PAD	_	PAD	75	JR	_	_
77	_	_	on	_	_	_	UO	_	UO	75	AN	_	_
78	_	_	the	_	_	_	UO	_	UO	77	HD	_	_
79	_	_	assessment	_	_	_	UO	_	UO	77	HD	_	_
80	_	_	of	_	_	_	UO	_	UO	77	HD	_	_
81	_	_	all	_	_	_	UO	_	UO	77	HD	_	_
82	_	_	advanced	_	_	_	UO	_	UO	77	HD	_	_
83	_	_	therapy	_	_	_	UO	_	UO	77	HD	_	_
84	_	_	medicinal	_	_	medicinal	NN	_	NN.UTR.SIN.IND.NOM	77	HD	_	_
85	_	_	products	_	_	_	UO	_	UO	77	HD	_	_
86	_	_	;	_	_	_	MID	_	MID	77	IS	_	_
87	_	_	some	_	_	_	UO	_	UO	77	AA	_	_
88	_	_	of	_	_	_	UO	_	UO	87	PA	_	_
89	_	_	the	_	_	_	UO	_	UO	88	HD	_	_
90	_	_	members	_	_	_	UO	_	UO	88	HD	_	_
91	_	_	of	_	_	_	UO	_	UO	88	HD	_	_
92	_	_	CAT	_	_	_	PM	_	PM.NOM	88	ET	_	_
93	_	_	should	_	_	_	UO	_	UO	92	PA	_	_
94	_	_	be	_	_	_	UO	_	UO	93	HD	_	_
95	_	_	elected	_	_	_	UO	_	UO	93	HD	_	_
96	_	_	among	_	_	_	PM	_	PM.NOM	93	ET	_	_
97	_	_	the	_	_	_	UO	_	UO	96	AN	_	_
98	_	_	members	_	_	_	UO	_	UO	97	HD	_	_
99	_	_	of	_	_	_	UO	_	UO	97	HD	_	_
100	_	_	the	_	_	_	UO	_	UO	97	HD	_	_
101	_	_	CHMP	_	_	_	PM	_	PM.NOM	102	CJ	_	_
102	_	_	,	_	_	_	MID	_	MID	97	PA	_	_
103	_	_	CAT	_	_	_	PM	_	PM.NOM	102	CJ	_	_
104	_	_	should	_	_	_	UO	_	UO	102	ET	_	_
105	_	_	also	_	_	_	UO	_	UO	104	HD	_	_
106	_	_	have	_	_	_	PM	_	PM.NOM	104	ET	_	_
107	_	_	members	_	_	_	UO	_	UO	106	PA	_	_
108	_	_	representing	_	_	_	UO	_	UO	107	HD	_	_
109	_	_	clinicians	_	_	_	NN	_	NN.UTR.SIN.DEF.GEN	107	HD	_	_
110	_	_	and	_	_	_	UO	_	UO	107	HD	_	_
111	_	_	patients	_	_	patient	NN	_	NN.UTR.SIN.IND.GEN	107	HD	_	_
112	_	_	associations	_	_	association	NN	_	NN.UTR.SIN.IND.GEN	107	HD	_	_
113	_	_	.	_	_	_	MAD	_	MAD	03	IP	_	_

# sent_id = 37
# text =  9.
1	_	_	9	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
2	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 38
# text =  Furthermore, the Working Party in this examination generally agreed to the following elements of the Proposal: a Committee for Advanced Therapies composed of members coming from all Member States; application to advanced therapies of the existing regulatory principles as regards clinical trials and good manufacturing practice, with appropriate adaptations at technical level; amendment of the existing pharmaceutical legislation to establish specific technical requirements as regards tissue engineered products; establishment of incentives related to scientific advice provided at a reduced fee, recommendation on classification of products, and certification of quality and non-clinical data.
1	_	_	Furthermore	_	_	_	PM	_	PM.NOM	0	ROOT	_	_
2	_	_	,	_	_	_	MID	_	MID	01	IK	_	_
3	_	_	the	_	_	_	PM	_	PM.NOM	05	DT	_	_
4	_	_	Working	_	_	_	PM	_	PM.NOM	03	HD	_	_
5	_	_	Party	_	_	party	NN	_	NN.NEU.SIN.IND.NOM	01	AN	_	_
6	_	_	in	_	_	_	UO	_	UO	05	ET	_	_
7	_	_	this	_	_	_	UO	_	UO	06	HD	_	_
8	_	_	examination	_	_	07	NN.UTR.SIN.IND.NOM	07	examination	NN	ROOT	_	_
9	_	_	generally	_	_	_	UO	_	UO	08	AA	_	_
10	_	_	agreed	_	_	_	UO	_	UO	09	AA	_	_
11	_	_	to	_	_	_	UO	_	UO	10	HD	_	_
12	_	_	the	_	_	_	UO	_	UO	11	AA	_	_
13	_	_	following	_	_	_	UO	_	UO	12	HD	_	_
14	_	_	elements	_	_	element	NN	_	NN.NEU.SIN.IND.GEN	15	DT	_	_
15	_	_	of	_	_	13	PM.NOM	13	_	PM	ROOT	_	_
16	_	_	the	_	_	_	PM	_	PM.NOM	15	HD	_	_
17	_	_	Proposal	_	_	_	PM	_	PM.NOM	15	HD	_	_
18	_	_	:	_	_	_	MID	_	MID	15	IQ	_	_
19	_	_	a	_	_	_	PM	_	PM.NOM	15	AN	_	_
20	_	_	Committee	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	19	HD	_	_
21	_	_	for	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	19	HD	_	_
22	_	_	Advanced	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	19	HD	_	_
23	_	_	Therapies	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	19	HD	_	_
24	_	_	composed	_	_	19	UO	19	_	UO	ROOT	_	_
25	_	_	of	_	_	_	UO	_	UO	24	HD	_	_
26	_	_	members	_	_	_	UO	_	UO	24	HD	_	_
27	_	_	coming	_	_	24	PM.NOM	24	_	PM	ROOT	_	_
28	_	_	from	_	_	27	UO	27	_	UO	ROOT	_	_
29	_	_	all	_	_	_	UO	_	UO	28	HD	_	_
30	_	_	Member	_	_	28	PM.NOM	28	_	PM	ROOT	_	_
31	_	_	States	_	_	30	UO	30	_	UO	ROOT	_	_
32	_	_	;	_	_	_	MID	_	MID	31	IS	_	_
33	_	_	application	_	_	_	UO	_	UO	31	HD	_	_
34	_	_	to	_	_	_	UO	_	UO	31	HD	_	_
35	_	_	advanced	_	_	_	UO	_	UO	31	HD	_	_
36	_	_	therapies	_	_	_	UO	_	UO	31	HD	_	_
37	_	_	of	_	_	_	UO	_	UO	31	HD	_	_
38	_	_	the	_	_	_	UO	_	UO	31	HD	_	_
39	_	_	existing	_	_	_	UO	_	UO	31	HD	_	_
40	_	_	regulatory	_	_	_	UO	_	UO	31	HD	_	_
41	_	_	principles	_	_	_	UO	_	UO	31	HD	_	_
42	_	_	as	_	_	_	UO	_	UO	31	HD	_	_
43	_	_	regards	_	_	_	UO	_	UO	31	HD	_	_
44	_	_	clinical	_	_	_	UO	_	UO	31	HD	_	_
45	_	_	trials	_	_	trial	NN	_	NN.UTR.SIN.IND.GEN	31	HD	_	_
46	_	_	and	_	_	_	UO	_	UO	31	HD	_	_
47	_	_	good	_	_	_	UO	_	UO	31	HD	_	_
48	_	_	manufacturing	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	31	HD	_	_
49	_	_	practice	_	_	_	UO	_	UO	31	HD	_	_
50	_	_	,	_	_	_	MID	_	MID	31	IK	_	_
51	_	_	with	_	_	_	UO	_	UO	56	DT	_	_
52	_	_	appropriate	_	_	_	UO	_	UO	51	HD	_	_
53	_	_	adaptations	_	_	adaptation	NN	_	NN.UTR.SIN.IND.GEN	51	HD	_	_
54	_	_	at	_	_	_	SN	_	SN	56	DT	_	_
55	_	_	technical	_	_	_	JJ	_	JJ.POS.UTR.SIN.IND.NOM	56	AT	_	_
56	_	_	level	_	_	level	NN	_	NN.UTR.SIN.IND.NOM	31	AN	_	_
57	_	_	;	_	_	_	MID	_	MID	56	IQ	_	_
58	_	_	amendment	_	_	_	UO	_	UO	56	ET	_	_
59	_	_	of	_	_	_	UO	_	UO	63	DT	_	_
60	_	_	the	_	_	_	UO	_	UO	59	HD	_	_
61	_	_	existing	_	_	_	UO	_	UO	59	HD	_	_
62	_	_	pharmaceutical	_	_	_	UO	_	UO	59	HD	_	_
63	_	_	legislation	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	58	PA	_	_
64	_	_	to	_	_	_	UO	_	UO	63	ET	_	_
65	_	_	establish	_	_	_	UO	_	UO	64	AA	_	_
66	_	_	specific	_	_	_	UO	_	UO	65	HD	_	_
67	_	_	technical	_	_	_	UO	_	UO	65	HD	_	_
68	_	_	requirements	_	_	_	UO	_	UO	65	HD	_	_
69	_	_	as	_	_	_	UO	_	UO	65	HD	_	_
70	_	_	regards	_	_	_	UO	_	UO	65	HD	_	_
71	_	_	tissue	_	_	_	UO	_	UO	65	HD	_	_
72	_	_	engineered	_	_	_	UO	_	UO	65	HD	_	_
73	_	_	products	_	_	_	UO	_	UO	65	HD	_	_
74	_	_	;	_	_	_	MID	_	MID	65	IS	_	_
75	_	_	establishment	_	_	_	UO	ENAMEX.FNC.LOC	UO	65	AA	_	_
76	_	_	of	_	_	_	UO	_	UO	75	HD	_	_
77	_	_	incentives	_	_	_	UO	_	UO	75	HD	_	_
78	_	_	related	_	_	_	UO	_	UO	75	HD	_	_
79	_	_	to	_	_	_	UO	_	UO	75	HD	_	_
80	_	_	scientific	_	_	_	UO	_	UO	75	HD	_	_
81	_	_	advice	_	_	_	UO	_	UO	75	HD	_	_
82	_	_	provided	_	_	_	UO	_	UO	75	HD	_	_
83	_	_	at	_	_	75	PM.NOM	75	_	PM	ROOT	_	_
84	_	_	a	_	_	83	UO	83	_	UO	ROOT	_	_
85	_	_	reduced	_	_	_	UO	_	UO	84	HD	_	_
86	_	_	fee	_	_	_	UO	_	UO	84	HD	_	_
87	_	_	,	_	_	_	MID	_	MID	84	IK	_	_
88	_	_	recommendation	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	84	MS	_	_
89	_	_	on	_	_	_	UO	_	UO	88	AN	_	_
90	_	_	classification	_	_	_	UO	_	UO	89	HD	_	_
91	_	_	of	_	_	_	UO	_	UO	90	HD	_	_
92	_	_	products	_	_	_	UO	_	UO	90	HD	_	_
93	_	_	,	_	_	_	MID	_	MID	90	IK	_	_
94	_	_	and	_	_	_	UO	_	UO	100	DT	_	_
95	_	_	certification	_	_	_	UO	_	UO	94	HD	_	_
96	_	_	of	_	_	_	UO	_	UO	94	HD	_	_
97	_	_	quality	_	_	_	UO	_	UO	94	HD	_	_
98	_	_	and	_	_	_	UO	_	UO	94	HD	_	_
99	_	_	non-clinical	_	_	_	UO	_	UO	100	DT	_	_
100	_	_	data	_	_	data	NN	_	NN.UTR.SIN.IND.NOM	90	AN	_	_
101	_	_	.	_	_	_	MAD	_	MAD	88	IP	_	_

# sent_id = 39
# text =  Combined products 10.
1	_	_	Combined	_	_	_	UO	_	UO	0	ROOT	_	_
2	_	_	products	_	_	_	UO	_	UO	3	DT	_	_
3	_	_	10	_	_	_	RG	_	RG.NOM	1	RA	_	_
4	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 40
# text =  The Working Party thoroughly discussed how to regulate combined products consisting of a medical device and viable cells or tissues of human or animal origin.
1	_	_	The	_	_	_	PM	_	PM.NOM	3	DT	_	_
2	_	_	Working	_	_	_	PM	_	PM.NOM	1	HD	_	_
3	_	_	Party	_	_	_	NN	_	NN.NEU.SIN.IND.NOM	0	ROOT	_	_
4	_	_	thoroughly	_	_	_	UO	_	UO	3	ET	_	_
5	_	_	discussed	_	_	_	UO	_	UO	25	DT	_	_
6	_	_	how	_	_	_	UO	_	UO	5	HD	_	_
7	_	_	to	_	_	_	UO	_	UO	5	HD	_	_
8	_	_	regulate	_	_	_	UO	_	UO	5	HD	_	_
9	_	_	combined	_	_	_	UO	_	UO	5	HD	_	_
10	_	_	products	_	_	_	UO	_	UO	5	HD	_	_
11	_	_	consisting	_	_	_	UO	_	UO	5	HD	_	_
12	_	_	of	_	_	_	UO	_	UO	5	HD	_	_
13	_	_	a	_	_	_	UO	_	UO	5	HD	_	_
14	_	_	medical	_	_	_	UO	ENAMEX.CRP.ORG	UO	5	HD	_	_
15	_	_	device	_	_	_	UO	_	UO	5	HD	_	_
16	_	_	and	_	_	_	UO	_	UO	5	HD	_	_
17	_	_	viable	_	_	_	UO	_	UO	5	HD	_	_
18	_	_	cells	_	_	cell	NN	_	NN.UTR.SIN.IND.GEN	5	HD	_	_
19	_	_	or	_	_	_	UO	_	UO	5	HD	_	_
20	_	_	tissues	_	_	_	UO	_	UO	5	HD	_	_
21	_	_	of	_	_	_	UO	_	UO	5	HD	_	_
22	_	_	human	_	_	human	JJ	_	JJ.POS.UTR.SIN.IND.NOM	25	DT	_	_
23	_	_	or	_	_	_	UO	_	UO	25	DT	_	_
24	_	_	animal	_	_	animal	JJ	_	JJ.POS.UTR.SIN.IND.NOM	25	AT	_	_
25	_	_	origin	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	4	UA	_	_
26	_	_	.	_	_	_	MAD	_	MAD	3	IP	_	_

# sent_id = 41
# text =  A majority of delegations, argued that - in view of the fact that viable cells contained in a combined product would always have a pharmacological, immunological or metabolic effect - all such products should fall under this regulation (Article 2 (1 (d))).
1	_	_	A	_	_	_	UO	_	UO	0	ROOT	_	_
2	_	_	majority	_	_	_	UO	_	UO	1	HD	_	_
3	_	_	of	_	_	_	UO	_	UO	4	DT	_	_
4	_	_	delegations	_	_	delegation	NN	_	NN.UTR.SIN.IND.GEN	2	SS	_	_
5	_	_	,	_	_	_	MID	_	MID	4	IK	_	_
6	_	_	argued	_	_	_	UO	_	UO	4	AN	_	_
7	_	_	that	_	_	_	UO	_	UO	6	HD	_	_
8	_	_	-	_	_	_	MID	_	MID	6	IT	_	_
9	_	_	in	_	_	_	UO	_	UO	6	AN	_	_
10	_	_	view	_	_	_	UO	_	UO	9	HD	_	_
11	_	_	of	_	_	_	UO	_	UO	9	HD	_	_
12	_	_	the	_	_	_	UO	_	UO	9	HD	_	_
13	_	_	fact	_	_	_	UO	_	UO	9	HD	_	_
14	_	_	that	_	_	_	UO	_	UO	9	HD	_	_
15	_	_	viable	_	_	_	UO	_	UO	9	HD	_	_
16	_	_	cells	_	_	cell	NN	_	NN.UTR.SIN.IND.GEN	9	HD	_	_
17	_	_	contained	_	_	_	UO	_	UO	9	HD	_	_
18	_	_	in	_	_	_	UO	_	UO	9	HD	_	_
19	_	_	a	_	_	_	UO	_	UO	9	HD	_	_
20	_	_	combined	_	_	_	UO	_	UO	9	HD	_	_
21	_	_	product	_	_	_	UO	_	UO	9	HD	_	_
22	_	_	would	_	_	_	UO	_	UO	9	HD	_	_
23	_	_	always	_	_	_	PM	_	PM.NOM	9	UA	_	_
24	_	_	have	_	_	_	PM	_	PM.NOM	23	HD	_	_
25	_	_	a	_	_	_	UO	_	UO	23	AN	_	_
26	_	_	pharmacological	_	_	_	UO	_	UO	25	HD	_	_
27	_	_	,	_	_	_	MID	_	MID	25	IK	_	_
28	_	_	immunological	_	_	_	UO	_	UO	25	HD	_	_
29	_	_	or	_	_	_	UO	_	UO	25	HD	_	_
30	_	_	metabolic	_	_	_	UO	_	UO	25	HD	_	_
31	_	_	effect	_	_	_	UO	_	UO	25	HD	_	_
32	_	_	-	_	_	_	MID	_	MID	25	IT	_	_
33	_	_	all	_	_	_	UO	_	UO	25	HD	_	_
34	_	_	such	_	_	_	UO	_	UO	33	HD	_	_
35	_	_	products	_	_	_	UO	_	UO	33	HD	_	_
36	_	_	should	_	_	_	UO	_	UO	33	HD	_	_
37	_	_	fall	_	_	fall	NN	_	NN.NEU.SIN.IND.NOM	33	HD	_	_
38	_	_	under	_	_	under	PP	_	PP	33	TA	_	_
39	_	_	this	_	_	_	UO	_	UO	40	DT	_	_
40	_	_	regulation	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	38	PA	_	_
41	_	_	(	_	_	_	PAD	_	PAD	25	IR	_	_
42	_	_	Article	_	_	_	PM	_	PM.NOM	25	ET	_	_
43	_	_	2	_	_	_	RG	_	RG.NOM	42	ET	_	_
44	_	_	(	_	_	_	PAD	_	PAD	43	IR	_	_
45	_	_	1	_	_	_	RG	_	RG.NOM	43	AN	_	_
46	_	_	(	_	_	_	PAD	_	PAD	45	IR	_	_
47	_	_	d	_	_	d	NN	_	NN.NEU.SIN.IND.NOM	45	AN	_	_
48	_	_	)	_	_	_	PAD	_	PAD	47	JR	_	_
49	_	_	)	_	_	_	PAD	_	PAD	45	JR	_	_
50	_	_	)	_	_	_	PAD	_	PAD	43	JR	_	_
51	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 42
# text =  This group further argued that the risks resulting from the use of such products were best handled through the legislation on medicinal products.
1	_	_	This	_	_	_	PM	_	PM.NOM	0	ROOT	_	_
2	_	_	group	_	_	_	PM	_	PM.NOM	1	HD	_	_
3	_	_	further	_	_	_	UO	_	UO	1	AN	_	_
4	_	_	argued	_	_	_	UO	_	UO	3	HD	_	_
5	_	_	that	_	_	_	UO	_	UO	3	HD	_	_
6	_	_	the	_	_	_	UO	_	UO	3	HD	_	_
7	_	_	risks	_	_	risk	NN	_	NN.UTR.SIN.IND.GEN	3	HD	_	_
8	_	_	resulting	_	_	_	UO	_	UO	3	HD	_	_
9	_	_	from	_	_	_	UO	_	UO	3	HD	_	_
10	_	_	the	_	_	_	UO	_	UO	3	HD	_	_
11	_	_	use	_	_	_	UO	_	UO	3	HD	_	_
12	_	_	of	_	_	_	UO	_	UO	3	HD	_	_
13	_	_	such	_	_	_	UO	_	UO	3	HD	_	_
14	_	_	products	_	_	_	UO	_	UO	3	HD	_	_
15	_	_	were	_	_	_	UO	_	UO	3	HD	_	_
16	_	_	best	_	_	best	NN	_	NN.UTR.SIN.IND.NOM	3	HD	_	_
17	_	_	handled	_	_	handled	NN	_	NN.UTR.SIN.IND.NOM	3	HD	_	_
18	_	_	through	_	_	_	UO	_	UO	3	HD	_	_
19	_	_	the	_	_	_	UO	_	UO	3	HD	_	_
20	_	_	legislation	_	_	_	NN	_	NN.UTR.SIN.DEF.NOM	3	HD	_	_
21	_	_	on	_	_	_	PM	_	PM.NOM	22	DT	_	_
22	_	_	medicinal	_	_	medicinal	NN	_	NN.NEU.SIN.IND.NOM	3	TA	_	_
23	_	_	products	_	_	_	UO	_	UO	22	ET	_	_
24	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 43
# text =  Several other delegations however stressed that the principal mode of action must determine whether a combined product should be regulated as a medical device or as a medicinal product, in line with the existing approach for regulating combination products.
1	_	_	Several	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	0	ROOT	_	_
2	_	_	other	_	_	_	UO	_	UO	1	PA	_	_
3	_	_	delegations	_	_	delegation	NN	_	NN.UTR.SIN.IND.GEN	2	SS	_	_
4	_	_	however	_	_	_	UO	_	UO	3	AN	_	_
5	_	_	stressed	_	_	_	UO	_	UO	4	HD	_	_
6	_	_	that	_	_	_	UO	_	UO	5	AA	_	_
7	_	_	the	_	_	_	UO	_	UO	8	DT	_	_
8	_	_	principal	_	_	principal	NN	_	NN.UTR.SIN.IND.NOM	6	PA	_	_
9	_	_	mode	_	_	_	UO	_	UO	8	ET	_	_
10	_	_	of	_	_	_	UO	_	UO	9	HD	_	_
11	_	_	action	_	_	action	NN	_	NN.UTR.SIN.IND.NOM	10	SS	_	_
12	_	_	must	_	_	_	UO	_	UO	11	AN	_	_
13	_	_	determine	_	_	_	UO	_	UO	12	HD	_	_
14	_	_	whether	_	_	_	UO	_	UO	13	HD	_	_
15	_	_	a	_	_	_	UO	_	UO	13	HD	_	_
16	_	_	combined	_	_	_	UO	_	UO	13	HD	_	_
17	_	_	product	_	_	_	UO	_	UO	13	HD	_	_
18	_	_	should	_	_	_	UO	_	UO	13	HD	_	_
19	_	_	be	_	_	_	UO	_	UO	13	HD	_	_
20	_	_	regulated	_	_	_	UO	_	UO	13	HD	_	_
21	_	_	as	_	_	_	UO	_	UO	13	HD	_	_
22	_	_	a	_	_	_	UO	_	UO	13	HD	_	_
23	_	_	medical	_	_	_	UO	ENAMEX.CRP.ORG	UO	13	HD	_	_
24	_	_	device	_	_	_	UO	_	UO	13	HD	_	_
25	_	_	or	_	_	_	UO	_	UO	13	HD	_	_
26	_	_	as	_	_	_	UO	_	UO	13	HD	_	_
27	_	_	a	_	_	_	UO	_	UO	13	HD	_	_
28	_	_	medicinal	_	_	medicinal	NN	_	NN.UTR.SIN.IND.NOM	13	HD	_	_
29	_	_	product	_	_	_	UO	_	UO	13	HD	_	_
30	_	_	,	_	_	_	MID	_	MID	12	IK	_	_
31	_	_	in	_	_	_	UO	_	UO	32	DT	_	_
32	_	_	line	_	_	_	PM	_	PM.NOM	37	SS	_	_
33	_	_	with	_	_	_	UO	_	UO	37	AA	_	_
34	_	_	the	_	_	_	UO	_	UO	33	HD	_	_
35	_	_	existing	_	_	_	UO	_	UO	33	HD	_	_
36	_	_	approach	_	_	approach	NN	_	NN.UTR.SIN.IND.NOM	33	HD	_	_
37	_	_	for	_	_	fara	VB	_	VB.PRT.AKT	12	MS	_	_
38	_	_	regulating	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	39	DT	_	_
39	_	_	combination	_	_	combination	NN	_	NN.UTR.SIN.IND.NOM	37	OO	_	_
40	_	_	products	_	_	_	UO	_	UO	37	SP	_	_
41	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 44
# text =  11.
1	_	_	11	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
2	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 45
# text =  The majority of the Working Party came to the preliminary conclusion that products containing non-viable material of human or animal origin and which act primarily by physical means should not be considered to be advanced therapy medicinal products, even though concerns about a possible legal gap were raised.
1	_	_	The	_	_	_	UO	_	UO	0	ROOT	_	_
2	_	_	majority	_	_	_	UO	_	UO	1	HD	_	_
3	_	_	of	_	_	_	UO	_	UO	2	AA	_	_
4	_	_	the	_	_	_	UO	_	UO	3	HD	_	_
5	_	_	Working	_	_	_	PM	_	PM.NOM	6	DT	_	_
6	_	_	Party	_	_	party	NN	_	NN.NEU.SIN.IND.NOM	3	PA	_	_
7	_	_	came	_	_	_	UO	_	UO	6	ET	_	_
8	_	_	to	_	_	_	UO	_	UO	7	HD	_	_
9	_	_	the	_	_	_	UO	_	UO	8	AA	_	_
10	_	_	preliminary	_	_	_	UO	_	UO	11	DT	_	_
11	_	_	conclusion	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	9	PA	_	_
12	_	_	that	_	_	_	UO	_	UO	11	ET	_	_
13	_	_	products	_	_	_	UO	_	UO	12	HD	_	_
14	_	_	containing	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	15	DT	_	_
15	_	_	non-viable	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	16	DT	_	_
16	_	_	material	_	_	material	NN	_	NN.NEU.SIN.IND.NOM	17	DT	_	_
17	_	_	of	_	_	_	PM	_	PM.NOM	13	UA	_	_
18	_	_	human	_	_	human	JJ	_	JJ.POS.UTR.SIN.IND.NOM	17	PT	_	_
19	_	_	or	_	_	_	UO	_	UO	18	PA	_	_
20	_	_	animal	_	_	animal	JJ	_	JJ.POS.UTR.SIN.IND.NOM	21	AT	_	_
21	_	_	origin	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	19	SS	_	_
22	_	_	and	_	_	_	UO	_	UO	21	AN	_	_
23	_	_	which	_	_	_	UO	_	UO	22	HD	_	_
24	_	_	act	_	_	_	UO	_	UO	23	HD	_	_
25	_	_	primarily	_	_	_	UO	_	UO	23	HD	_	_
26	_	_	by	_	_	_	UO	_	UO	23	HD	_	_
27	_	_	physical	_	_	_	UO	_	UO	23	HD	_	_
28	_	_	means	_	_	_	UO	_	UO	23	HD	_	_
29	_	_	should	_	_	_	UO	_	UO	23	HD	_	_
30	_	_	not	_	_	_	UO	_	UO	23	HD	_	_
31	_	_	be	_	_	_	UO	_	UO	23	HD	_	_
32	_	_	considered	_	_	_	UO	_	UO	23	HD	_	_
33	_	_	to	_	_	_	UO	_	UO	23	HD	_	_
34	_	_	be	_	_	_	UO	_	UO	23	HD	_	_
35	_	_	advanced	_	_	_	UO	_	UO	23	HD	_	_
36	_	_	therapy	_	_	_	UO	_	UO	23	HD	_	_
37	_	_	medicinal	_	_	medicinal	NN	_	NN.UTR.SIN.IND.NOM	23	HD	_	_
38	_	_	products	_	_	_	UO	_	UO	23	HD	_	_
39	_	_	,	_	_	_	MID	_	MID	23	IK	_	_
40	_	_	even	_	_	_	NN	_	NN.UTR.SIN.DEF.NOM	23	AN	_	_
41	_	_	though	_	_	_	UO	_	UO	40	PA	_	_
42	_	_	concerns	_	_	_	NN	_	NN.UTR.SIN.DEF.GEN	41	SS	_	_
43	_	_	about	_	_	_	UO	_	UO	42	AN	_	_
44	_	_	a	_	_	_	UO	_	UO	43	HD	_	_
45	_	_	possible	_	_	_	UO	_	UO	47	DT	_	_
46	_	_	legal	_	_	legal	JJ	_	JJ.POS.UTR.SIN.IND.NOM	47	AT	_	_
47	_	_	gap	_	_	gap	NN	_	NN.NEU.SIN.IND.NOM	44	SS	_	_
48	_	_	were	_	_	_	UO	_	UO	47	ET	_	_
49	_	_	raised	_	_	_	UO	_	UO	48	HD	_	_
50	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 46
# text =  12.
1	_	_	12	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
2	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 47
# text =  There was broad agreement that, subject to further examination of how to ensure that all necessary medical device expertise could be brought into the evaluation procedure, combined advanced therapy products falling under the present Regulation should be assessed as a whole under the auspices of the EMEA (" one stop shop ").
1	_	_	There	_	_	_	UO	_	UO	4	DT	_	_
2	_	_	was	_	_	_	UO	_	UO	1	HD	_	_
3	_	_	broad	_	_	broa	PC	_	PC.PRF.UTR.SIN.IND.NOM	4	AT	_	_
4	_	_	agreement	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	0	ROOT	_	_
5	_	_	that	_	_	_	UO	_	UO	4	ET	_	_
6	_	_	,	_	_	_	MID	_	MID	5	IK	_	_
7	_	_	subject	_	_	_	UO	_	UO	5	AN	_	_
8	_	_	to	_	_	_	UO	_	UO	7	AN	_	_
9	_	_	further	_	_	_	UO	_	UO	8	HD	_	_
10	_	_	examination	_	_	examination	NN	_	NN.UTR.SIN.IND.NOM	9	SS	_	_
11	_	_	of	_	_	_	UO	_	UO	10	AN	_	_
12	_	_	how	_	_	_	UO	_	UO	11	HD	_	_
13	_	_	to	_	_	_	UO	_	UO	12	HD	_	_
14	_	_	ensure	_	_	_	UO	_	UO	12	HD	_	_
15	_	_	that	_	_	_	UO	_	UO	12	HD	_	_
16	_	_	all	_	_	_	UO	_	UO	12	HD	_	_
17	_	_	necessary	_	_	_	UO	_	UO	12	HD	_	_
18	_	_	medical	_	_	_	UO	ENAMEX.CRP.ORG	UO	12	HD	_	_
19	_	_	device	_	_	_	UO	_	UO	12	HD	_	_
20	_	_	expertise	_	_	_	UO	_	UO	12	HD	_	_
21	_	_	could	_	_	_	UO	_	UO	12	HD	_	_
22	_	_	be	_	_	_	UO	_	UO	12	HD	_	_
23	_	_	brought	_	_	_	UO	_	UO	12	HD	_	_
24	_	_	into	_	_	_	PM	_	PM.NOM	26	DT	_	_
25	_	_	the	_	_	_	PM	_	PM.NOM	24	HD	_	_
26	_	_	evaluation	_	_	_	NN	_	NN.UTR.SIN.DEF.NOM	12	TA	_	_
27	_	_	procedure	_	_	_	UO	_	UO	26	ET	_	_
28	_	_	,	_	_	_	MID	_	MID	27	IK	_	_
29	_	_	combined	_	_	_	UO	_	UO	27	AN	_	_
30	_	_	advanced	_	_	_	UO	_	UO	29	HD	_	_
31	_	_	therapy	_	_	_	UO	_	UO	29	HD	_	_
32	_	_	products	_	_	_	UO	_	UO	29	HD	_	_
33	_	_	falling	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	29	HD	_	_
34	_	_	under	_	_	under	PP	_	PP	29	TA	_	_
35	_	_	the	_	_	_	PM	_	PM.NOM	36	DT	_	_
36	_	_	present	_	_	present	NN	_	NN.UTR.SIN.IND.NOM	34	PA	_	_
37	_	_	Regulation	_	_	_	UO	_	UO	36	ET	_	_
38	_	_	should	_	_	_	UO	_	UO	37	HD	_	_
39	_	_	be	_	_	_	UO	_	UO	38	HD	_	_
40	_	_	assessed	_	_	_	UO	_	UO	38	HD	_	_
41	_	_	as	_	_	_	UO	_	UO	38	HD	_	_
42	_	_	a	_	_	_	UO	_	UO	38	HD	_	_
43	_	_	whole	_	_	_	UO	_	UO	38	HD	_	_
44	_	_	under	_	_	_	UO	_	UO	38	HD	_	_
45	_	_	the	_	_	_	UO	_	UO	38	HD	_	_
46	_	_	auspices	_	_	_	UO	_	UO	38	HD	_	_
47	_	_	of	_	_	_	UO	_	UO	38	HD	_	_
48	_	_	the	_	_	_	UO	_	UO	38	HD	_	_
49	_	_	EMEA	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	38	AN	_	_
50	_	_	(	_	_	_	PAD	_	PAD	49	IR	_	_
51	_	_	"	_	_	_	PAD	_	PAD	53	DT	_	_
52	_	_	one	_	_	_	PM	_	PM.NOM	51	HD	_	_
53	_	_	stop	_	_	stop	NN	_	NN.NEU.SIN.IND.NOM	49	AN	_	_
54	_	_	shop	_	_	_	UO	_	UO	53	HD	_	_
55	_	_	"	_	_	_	PAD	_	PAD	53	JC	_	_
56	_	_	)	_	_	_	PAD	_	PAD	49	JR	_	_
57	_	_	.	_	_	_	MAD	_	MAD	4	IP	_	_

# sent_id = 48
# text =  Hospital exemption 13.
1	_	_	Hospital	_	_	_	NN	_	NN.NEU.SIN.IND.NOM	0	ROOT	_	_
2	_	_	exemption	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	3	DT	_	_
3	_	_	13	_	_	_	RG	_	RG.NOM	1	RA	_	_
4	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 49
# text =  Point (1) of Article 28 introduces an exemption from the requirements of Directive 2001 / 83 / EC on the Community code relating to medicinal products for human use, for advanced therapy medicinal products that are both prepared in full and used within the same hospital, provided that this takes place in accordance with a medical prescription for an individual patient.
1	_	_	Point	_	_	_	PM	_	PM.NOM	3	ET	_	_
2	_	_	(	_	_	_	PAD	_	PAD	1	IR	_	_
3	_	_	1	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
4	_	_	)	_	_	_	PAD	_	PAD	3	JR	_	_
5	_	_	of	_	_	_	UO	_	UO	7	AA	_	_
6	_	_	Article	_	_	_	UO	_	UO	5	HD	_	_
7	_	_	28	_	_	_	RG	_	RG.NOM	10	DT	_	_
8	_	_	introduces	_	_	_	UO	_	UO	10	DT	_	_
9	_	_	an	_	_	_	UO	_	UO	8	HD	_	_
10	_	_	exemption	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	1	AN	_	_
11	_	_	from	_	_	_	UO	_	UO	10	ET	_	_
12	_	_	the	_	_	_	UO	_	UO	11	HD	_	_
13	_	_	requirements	_	_	_	UO	_	UO	12	HD	_	_
14	_	_	of	_	_	_	UO	_	UO	12	HD	_	_
15	_	_	Directive	_	_	_	PM	_	PM.NOM	12	OO	_	_
16	_	_	2001	_	_	_	RG	_	RG.NOM	15	ET	_	_
17	_	_	/	_	_	_	MID	_	MID	16	IK	_	_
18	_	_	83	_	_	_	RG	_	RG.NOM	16	RA	_	_
19	_	_	/	_	_	_	MID	_	MID	18	ET	_	_
20	_	_	EC	_	_	_	PM	_	PM.NOM	19	UA	_	_
21	_	_	on	_	_	_	PM	_	PM.NOM	20	HD	_	_
22	_	_	the	_	_	_	PM	_	PM.NOM	20	HD	_	_
23	_	_	Community	_	_	_	PM	_	PM.NOM	20	HD	_	_
24	_	_	code	_	_	_	UO	_	UO	20	AN	_	_
25	_	_	relating	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	26	DT	_	_
26	_	_	to	_	_	_	PM	_	PM.NOM	24	SS	_	_
27	_	_	medicinal	_	_	medicinal	NN	_	NN.NEU.SIN.IND.NOM	26	HD	_	_
28	_	_	products	_	_	_	UO	_	UO	26	AN	_	_
29	_	_	for	_	_	_	UO	_	UO	28	HD	_	_
30	_	_	human	_	_	human	JJ	_	JJ.POS.UTR.SIN.IND.NOM	28	HD	_	_
31	_	_	use	_	_	_	UO	_	UO	28	HD	_	_
32	_	_	,	_	_	_	MID	_	MID	28	IK	_	_
33	_	_	for	_	_	_	UO	_	UO	28	AA	_	_
34	_	_	advanced	_	_	_	UO	_	UO	33	AN	_	_
35	_	_	therapy	_	_	_	UO	_	UO	34	HD	_	_
36	_	_	medicinal	_	_	medicinal	NN	_	NN.UTR.SIN.IND.NOM	35	SS	_	_
37	_	_	products	_	_	_	UO	_	UO	36	ET	_	_
38	_	_	that	_	_	_	UO	_	UO	49	DT	_	_
39	_	_	are	_	_	_	UO	_	UO	38	HD	_	_
40	_	_	both	_	_	_	UO	_	UO	38	HD	_	_
41	_	_	prepared	_	_	_	UO	_	UO	38	HD	_	_
42	_	_	in	_	_	_	UO	_	UO	38	HD	_	_
43	_	_	full	_	_	_	UO	_	UO	38	HD	_	_
44	_	_	and	_	_	_	UO	_	UO	38	HD	_	_
45	_	_	used	_	_	_	UO	_	UO	38	HD	_	_
46	_	_	within	_	_	_	UO	_	UO	38	HD	_	_
47	_	_	the	_	_	_	UO	_	UO	38	HD	_	_
48	_	_	same	_	_	same	NN	_	NN.UTR.SIN.IND.NOM	38	HD	_	_
49	_	_	hospital	_	_	hospital	NN	_	NN.NEU.SIN.IND.NOM	37	UA	_	_
50	_	_	,	_	_	_	MID	_	MID	49	IK	_	_
51	_	_	provided	_	_	_	UO	_	UO	49	ET	_	_
52	_	_	that	_	_	_	UO	_	UO	65	DT	_	_
53	_	_	this	_	_	_	UO	_	UO	52	HD	_	_
54	_	_	takes	_	_	_	UO	_	UO	52	HD	_	_
55	_	_	place	_	_	_	PM	_	PM.NOM	65	DT	_	_
56	_	_	in	_	_	_	UO	_	UO	65	DT	_	_
57	_	_	accordance	_	_	_	UO	_	UO	56	HD	_	_
58	_	_	with	_	_	_	UO	_	UO	56	HD	_	_
59	_	_	a	_	_	_	UO	_	UO	56	HD	_	_
60	_	_	medical	_	_	_	UO	ENAMEX.CRP.ORG	UO	56	HD	_	_
61	_	_	prescription	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	56	HD	_	_
62	_	_	for	_	_	_	UO	_	UO	56	HD	_	_
63	_	_	an	_	_	_	UO	_	UO	56	HD	_	_
64	_	_	individual	_	_	_	UO	_	UO	65	DT	_	_
65	_	_	patient	_	_	patient	NN	_	NN.UTR.SIN.IND.NOM	51	UA	_	_
66	_	_	.	_	_	_	MAD	_	MAD	3	IP	_	_

# sent_id = 50
# text =  As an example, products prepared in a pharmaceutical enterprise not falling under this exemption would require clinical trials in order to receive a marketing authorisation before being used, but similar products prepared for the same use under the exemption would not.
1	_	_	As	_	_	_	UO	_	UO	0	ROOT	_	_
2	_	_	an	_	_	_	UO	_	UO	1	HD	_	_
3	_	_	example	_	_	_	UO	_	UO	2	HD	_	_
4	_	_	,	_	_	_	MID	_	MID	2	IK	_	_
5	_	_	products	_	_	_	UO	_	UO	2	AN	_	_
6	_	_	prepared	_	_	_	UO	_	UO	5	HD	_	_
7	_	_	in	_	_	_	UO	_	UO	5	HD	_	_
8	_	_	a	_	_	_	UO	_	UO	5	HD	_	_
9	_	_	pharmaceutical	_	_	_	UO	_	UO	5	HD	_	_
10	_	_	enterprise	_	_	_	UO	_	UO	5	HD	_	_
11	_	_	not	_	_	_	UO	_	UO	5	HD	_	_
12	_	_	falling	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	5	HD	_	_
13	_	_	under	_	_	under	PP	_	PP	5	TA	_	_
14	_	_	this	_	_	_	UO	_	UO	13	PA	_	_
15	_	_	exemption	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	14	SS	_	_
16	_	_	would	_	_	_	UO	_	UO	15	ET	_	_
17	_	_	require	_	_	_	UO	_	UO	21	DT	_	_
18	_	_	clinical	_	_	_	UO	_	UO	17	HD	_	_
19	_	_	trials	_	_	trial	NN	_	NN.UTR.SIN.IND.GEN	17	HD	_	_
20	_	_	in	_	_	_	UO	_	UO	17	HD	_	_
21	_	_	order	_	_	order	NN	_	NN.UTR.SIN.IND.NOM	16	UA	_	_
22	_	_	to	_	_	_	UO	_	UO	21	ET	_	_
23	_	_	receive	_	_	_	UO	_	UO	22	HD	_	_
24	_	_	a	_	_	_	UO	_	UO	25	DT	_	_
25	_	_	marketing	_	_	marketing	NN	_	NN.UTR.SIN.IND.NOM	26	DT	_	_
26	_	_	authorisation	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	27	SS	_	_
27	_	_	before	_	_	befara	VB	_	VB.PRT.AKT	23	OO	_	_
28	_	_	being	_	_	_	JJ	_	JJ.POS.UTR.SIN.IND.NOM	27	SP	_	_
29	_	_	used	_	_	_	UO	_	UO	27	SP	_	_
30	_	_	,	_	_	_	MID	_	MID	29	IK	_	_
31	_	_	but	_	_	_	UO	_	UO	29	AN	_	_
32	_	_	similar	_	_	simil	NN	_	NN.UTR.PLU.IND.NOM	31	SS	_	_
33	_	_	products	_	_	_	UO	_	UO	32	AN	_	_
34	_	_	prepared	_	_	_	UO	_	UO	33	HD	_	_
35	_	_	for	_	_	_	UO	_	UO	34	AA	_	_
36	_	_	the	_	_	_	UO	_	UO	37	DT	_	_
37	_	_	same	_	_	same	NN	_	NN.UTR.SIN.IND.NOM	35	PA	_	_
38	_	_	use	_	_	_	UO	_	UO	37	ET	_	_
39	_	_	under	_	_	_	UO	_	UO	38	HD	_	_
40	_	_	the	_	_	_	UO	_	UO	41	DT	_	_
41	_	_	exemption	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	39	SS	_	_
42	_	_	would	_	_	_	UO	_	UO	41	ET	_	_
43	_	_	not	_	_	_	UO	_	UO	42	HD	_	_
44	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 51
# text =  Some delegations, while in favour of the principal idea behind such an exemption, saw a need for further examination.
1	_	_	Some	_	_	_	UO	_	UO	0	ROOT	_	_
2	_	_	delegations	_	_	delegation	NN	_	NN.UTR.SIN.IND.GEN	1	SS	_	_
3	_	_	,	_	_	_	MID	_	MID	2	IK	_	_
4	_	_	while	_	_	_	UO	_	UO	2	AN	_	_
5	_	_	in	_	_	_	UO	_	UO	4	HD	_	_
6	_	_	favour	_	_	_	UO	_	UO	5	HD	_	_
7	_	_	of	_	_	_	UO	_	UO	5	HD	_	_
8	_	_	the	_	_	_	UO	_	UO	5	HD	_	_
9	_	_	principal	_	_	principal	NN	_	NN.UTR.SIN.IND.NOM	10	DT	_	_
10	_	_	idea	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	11	DT	_	_
11	_	_	behind	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	5	OO	_	_
12	_	_	such	_	_	_	UO	_	UO	11	ET	_	_
13	_	_	an	_	_	_	UO	_	UO	14	DT	_	_
14	_	_	exemption	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	12	PA	_	_
15	_	_	,	_	_	_	MID	_	MID	14	IK	_	_
16	_	_	saw	_	_	_	UO	_	UO	14	ET	_	_
17	_	_	a	_	_	_	UO	_	UO	21	DT	_	_
18	_	_	need	_	_	_	UO	_	UO	17	HD	_	_
19	_	_	for	_	_	_	UO	_	UO	17	HD	_	_
20	_	_	further	_	_	_	UO	_	UO	21	DT	_	_
21	_	_	examination	_	_	examination	NN	_	NN.UTR.SIN.IND.NOM	16	UA	_	_
22	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 52
# text =  Other delegations argued in favour of enlarging this exemption to products prepared and used in a network of hospitals.
1	_	_	Other	_	_	_	UO	_	UO	0	ROOT	_	_
2	_	_	delegations	_	_	delegation	NN	_	NN.UTR.SIN.IND.GEN	1	SS	_	_
3	_	_	argued	_	_	_	UO	_	UO	2	AN	_	_
4	_	_	in	_	_	_	UO	_	UO	3	AN	_	_
5	_	_	favour	_	_	_	UO	_	UO	4	HD	_	_
6	_	_	of	_	_	_	UO	_	UO	7	DT	_	_
7	_	_	enlarging	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	5	SS	_	_
8	_	_	this	_	_	_	UO	_	UO	7	PA	_	_
9	_	_	exemption	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	8	SS	_	_
10	_	_	to	_	_	_	UO	_	UO	9	AN	_	_
11	_	_	products	_	_	_	UO	_	UO	10	ET	_	_
12	_	_	prepared	_	_	_	UO	_	UO	19	DT	_	_
13	_	_	and	_	_	_	UO	_	UO	12	HD	_	_
14	_	_	used	_	_	_	UO	_	UO	12	HD	_	_
15	_	_	in	_	_	_	UO	_	UO	12	HD	_	_
16	_	_	a	_	_	_	UO	_	UO	12	HD	_	_
17	_	_	network	_	_	_	UO	_	UO	12	HD	_	_
18	_	_	of	_	_	_	UO	_	UO	19	DT	_	_
19	_	_	hospitals	_	_	hospital	NN	_	NN.NEU.SIN.IND.GEN	11	UA	_	_
20	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 53
# text =  A third group of delegations preferred to widen the scope of the Regulation by deleting the proposed exemption.
1	_	_	A	_	_	_	IN	_	IN	0	ROOT	_	_
2	_	_	third	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	3	DT	_	_
3	_	_	group	_	_	_	PM	_	PM.NOM	5	DT	_	_
4	_	_	of	_	_	_	PM	_	PM.NOM	3	HD	_	_
5	_	_	delegations	_	_	delegation	NN	_	NN.UTR.SIN.IND.GEN	1	SS	_	_
6	_	_	preferred	_	_	_	UO	_	UO	5	ET	_	_
7	_	_	to	_	_	_	UO	_	UO	6	HD	_	_
8	_	_	widen	_	_	_	NN	_	NN.UTR.SIN.DEF.NOM	7	SS	_	_
9	_	_	the	_	_	_	UO	_	UO	8	AN	_	_
10	_	_	scope	_	_	_	UO	_	UO	9	HD	_	_
11	_	_	of	_	_	_	UO	_	UO	15	DT	_	_
12	_	_	the	_	_	_	UO	_	UO	11	HD	_	_
13	_	_	Regulation	_	_	_	UO	_	UO	11	HD	_	_
14	_	_	by	_	_	_	UO	_	UO	11	HD	_	_
15	_	_	deleting	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	18	DT	_	_
16	_	_	the	_	_	_	UO	_	UO	18	DT	_	_
17	_	_	proposed	_	_	_	UO	_	UO	18	DT	_	_
18	_	_	exemption	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	10	OP	_	_
19	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 54
# text =  Further examination of this point therefore seems necessary, in particular as concerns the understanding of the concepts involved, e.g. of industrial production in the specific context of advanced therapies, and as concerns the desirability and scope of the exemption.
1	_	_	Further	_	_	_	PM	_	PM.NOM	0	ROOT	_	_
2	_	_	examination	_	_	examination	NN	_	NN.UTR.SIN.IND.NOM	7	SS	_	_
3	_	_	of	_	_	_	UO	_	UO	7	AA	_	_
4	_	_	this	_	_	_	UO	_	UO	3	HD	_	_
5	_	_	point	_	_	_	UO	_	UO	4	HD	_	_
6	_	_	therefore	_	_	_	UO	_	UO	4	HD	_	_
7	_	_	seems	_	_	_	VB	_	VB.PRS.SFO	1	ET	_	_
8	_	_	necessary	_	_	_	UO	_	UO	7	OO	_	_
9	_	_	,	_	_	_	MID	_	MID	8	IK	_	_
10	_	_	in	_	_	_	UO	_	UO	8	AN	_	_
11	_	_	particular	_	_	_	UO	_	UO	10	AN	_	_
12	_	_	as	_	_	_	UO	_	UO	11	HD	_	_
13	_	_	concerns	_	_	_	NN	_	NN.UTR.SIN.DEF.GEN	12	SS	_	_
14	_	_	the	_	_	_	UO	_	UO	13	AN	_	_
15	_	_	understanding	_	_	_	UO	_	UO	14	HD	_	_
16	_	_	of	_	_	_	UO	_	UO	15	AA	_	_
17	_	_	the	_	_	_	UO	_	UO	18	DT	_	_
18	_	_	concepts	_	_	_	NN	_	NN.NEU.SIN.DEF.GEN	16	PA	_	_
19	_	_	involved	_	_	_	UO	_	UO	18	ET	_	_
20	_	_	,	_	_	_	MID	_	MID	19	IK	_	_
21	_	_	e.g.	_	_	_	UO	_	UO	19	AN	_	_
22	_	_	of	_	_	_	UO	_	UO	21	HD	_	_
23	_	_	industrial	_	_	_	UO	_	UO	21	HD	_	_
24	_	_	production	_	_	_	UO	_	UO	21	HD	_	_
25	_	_	in	_	_	_	UO	_	UO	21	HD	_	_
26	_	_	the	_	_	_	UO	_	UO	21	HD	_	_
27	_	_	specific	_	_	_	UO	_	UO	21	HD	_	_
28	_	_	context	_	_	_	UO	_	UO	21	HD	_	_
29	_	_	of	_	_	_	UO	_	UO	21	HD	_	_
30	_	_	advanced	_	_	_	UO	_	UO	21	HD	_	_
31	_	_	therapies	_	_	_	UO	_	UO	21	HD	_	_
32	_	_	,	_	_	_	MID	_	MID	19	IK	_	_
33	_	_	and	_	_	_	UO	_	UO	19	AN	_	_
34	_	_	as	_	_	_	UO	_	UO	33	HD	_	_
35	_	_	concerns	_	_	_	NN	_	NN.UTR.SIN.DEF.GEN	34	SS	_	_
36	_	_	the	_	_	_	UO	_	UO	35	ET	_	_
37	_	_	desirability	_	_	_	UO	_	UO	42	DT	_	_
38	_	_	and	_	_	_	UO	_	UO	37	HD	_	_
39	_	_	scope	_	_	_	UO	_	UO	37	HD	_	_
40	_	_	of	_	_	_	UO	_	UO	37	HD	_	_
41	_	_	the	_	_	_	UO	_	UO	42	DT	_	_
42	_	_	exemption	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	36	UA	_	_
43	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 55
# text =  Other considerations 14.
1	_	_	Other	_	_	_	UO	_	UO	0	ROOT	_	_
2	_	_	considerations	_	_	_	UO	_	UO	3	DT	_	_
3	_	_	14	_	_	_	RG	_	RG.NOM	1	RA	_	_
4	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 56
# text =  The annexes of the Regulation are subject to adaptation in view of scientific and technical progress through a comitology procedure.
1	_	_	The	_	_	_	UO	_	UO	0	ROOT	_	_
2	_	_	annexes	_	_	_	UO	_	UO	1	HD	_	_
3	_	_	of	_	_	_	UO	_	UO	2	HD	_	_
4	_	_	the	_	_	_	UO	_	UO	3	HD	_	_
5	_	_	Regulation	_	_	_	UO	_	UO	3	HD	_	_
6	_	_	are	_	_	_	UO	_	UO	3	HD	_	_
7	_	_	subject	_	_	_	UO	_	UO	3	HD	_	_
8	_	_	to	_	_	_	UO	_	UO	3	HD	_	_
9	_	_	adaptation	_	_	adaptation	NN	_	NN.UTR.SIN.IND.NOM	3	HD	_	_
10	_	_	in	_	_	_	UO	_	UO	3	HD	_	_
11	_	_	view	_	_	_	UO	_	UO	3	HD	_	_
12	_	_	of	_	_	_	UO	_	UO	3	HD	_	_
13	_	_	scientific	_	_	_	UO	_	UO	3	HD	_	_
14	_	_	and	_	_	_	UO	_	UO	3	HD	_	_
15	_	_	technical	_	_	_	UO	_	UO	3	HD	_	_
16	_	_	progress	_	_	progress	NN	_	NN.UTR.SIN.IND.NOM	3	HD	_	_
17	_	_	through	_	_	_	UO	_	UO	3	HD	_	_
18	_	_	a	_	_	_	UO	_	UO	3	HD	_	_
19	_	_	comitology	_	_	_	UO	_	UO	3	AN	_	_
20	_	_	procedure	_	_	_	UO	_	UO	19	HD	_	_
21	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 57
# text =  Since the decision on the scope of the Regulation must remain the competence of the legislator, it was further concluded that the parts of the present Annex I that define tissue engineered products must be included in the legal text itself.
1	_	_	Since	_	_	_	PM	_	PM.NOM	3	DT	_	_
2	_	_	the	_	_	_	PM	_	PM.NOM	1	HD	_	_
3	_	_	decision	_	_	_	NN	_	NN.UTR.SIN.DEF.NOM	0	ROOT	_	_
4	_	_	on	_	_	_	UO	_	UO	3	ET	_	_
5	_	_	the	_	_	_	UO	_	UO	4	HD	_	_
6	_	_	scope	_	_	_	UO	_	UO	5	HD	_	_
7	_	_	of	_	_	_	UO	_	UO	5	HD	_	_
8	_	_	the	_	_	_	UO	_	UO	5	HD	_	_
9	_	_	Regulation	_	_	_	UO	_	UO	5	HD	_	_
10	_	_	must	_	_	_	UO	_	UO	5	HD	_	_
11	_	_	remain	_	_	_	UO	_	UO	5	HD	_	_
12	_	_	the	_	_	_	UO	_	UO	5	HD	_	_
13	_	_	competence	_	_	_	UO	_	UO	5	HD	_	_
14	_	_	of	_	_	_	UO	_	UO	5	HD	_	_
15	_	_	the	_	_	_	UO	_	UO	5	HD	_	_
16	_	_	legislator	_	_	_	NN	_	NN.UTR.PLU.IND.NOM	5	HD	_	_
17	_	_	,	_	_	_	MID	_	MID	4	IK	_	_
18	_	_	it	_	_	_	UO	_	UO	42	AA	_	_
19	_	_	was	_	_	_	UO	_	UO	18	HD	_	_
20	_	_	further	_	_	_	UO	_	UO	18	HD	_	_
21	_	_	concluded	_	_	_	UO	_	UO	18	HD	_	_
22	_	_	that	_	_	_	UO	_	UO	18	HD	_	_
23	_	_	the	_	_	_	UO	_	UO	18	HD	_	_
24	_	_	parts	_	_	part	NN	_	NN.UTR.SIN.IND.GEN	18	HD	_	_
25	_	_	of	_	_	_	UO	_	UO	18	HD	_	_
26	_	_	the	_	_	_	UO	_	UO	18	HD	_	_
27	_	_	present	_	_	present	NN	_	NN.UTR.SIN.IND.NOM	18	HD	_	_
28	_	_	Annex	_	_	annex	NN	ENAMEX.HUM.PRS	NN.NEU.SIN.IND.NOM	42	DT	_	_
29	_	_	I	_	_	i	PP	ENAMEX.HUM.PRS	PP	28	ET	_	_
30	_	_	that	_	_	_	UO	_	UO	41	DT	_	_
31	_	_	define	_	_	_	UO	_	UO	30	HD	_	_
32	_	_	tissue	_	_	_	UO	_	UO	30	HD	_	_
33	_	_	engineered	_	_	_	UO	_	UO	30	HD	_	_
34	_	_	products	_	_	_	UO	_	UO	30	HD	_	_
35	_	_	must	_	_	_	UO	_	UO	30	HD	_	_
36	_	_	be	_	_	_	UO	_	UO	30	HD	_	_
37	_	_	included	_	_	_	UO	_	UO	30	HD	_	_
38	_	_	in	_	_	_	UO	_	UO	30	HD	_	_
39	_	_	the	_	_	_	UO	_	UO	30	HD	_	_
40	_	_	legal	_	_	legal	JJ	_	JJ.POS.UTR.SIN.IND.NOM	41	AT	_	_
41	_	_	text	_	_	text	NN	_	NN.UTR.SIN.IND.NOM	29	PA	_	_
42	_	_	itself	_	_	4	JJ.POS.UTR.SIN.IND.NOM	4	_	JJ	ROOT	_	_
43	_	_	.	_	_	_	MAD	_	MAD	42	IP	_	_

# sent_id = 58
# text =  There is general agreement that the list of non-substantial manipulations, which must remain subject to adaptation, should be indicative and reviewed for its scientific correctness.
1	_	_	There	_	_	_	UO	_	UO	0	ROOT	_	_
2	_	_	is	_	_	_	UO	_	UO	1	AA	_	_
3	_	_	general	_	_	general	NN	_	NN.UTR.SIN.IND.NOM	4	DT	_	_
4	_	_	agreement	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	2	PA	_	_
5	_	_	that	_	_	_	UO	_	UO	4	ET	_	_
6	_	_	the	_	_	_	UO	_	UO	5	HD	_	_
7	_	_	list	_	_	list	NN	_	NN.UTR.SIN.IND.NOM	8	DT	_	_
8	_	_	of	_	_	_	PM	_	PM.NOM	10	DT	_	_
9	_	_	non-substantial	_	_	_	JJ	_	JJ.POS.UTR.SIN.IND.NOM	10	DT	_	_
10	_	_	manipulations	_	_	manipulation	NN	_	NN.UTR.SIN.IND.GEN	6	SS	_	_
11	_	_	,	_	_	_	MID	_	MID	10	IK	_	_
12	_	_	which	_	_	_	UO	_	UO	10	ET	_	_
13	_	_	must	_	_	_	UO	_	UO	17	DT	_	_
14	_	_	remain	_	_	_	UO	_	UO	13	HD	_	_
15	_	_	subject	_	_	_	UO	_	UO	13	HD	_	_
16	_	_	to	_	_	_	UO	_	UO	13	HD	_	_
17	_	_	adaptation	_	_	adaptation	NN	_	NN.UTR.SIN.IND.NOM	12	UA	_	_
18	_	_	,	_	_	_	MID	_	MID	17	IK	_	_
19	_	_	should	_	_	_	UO	_	UO	17	AN	_	_
20	_	_	be	_	_	_	UO	_	UO	19	AN	_	_
21	_	_	indicative	_	_	_	UO	_	UO	20	HD	_	_
22	_	_	and	_	_	_	UO	_	UO	21	HD	_	_
23	_	_	reviewed	_	_	_	UO	_	UO	21	HD	_	_
24	_	_	for	_	_	_	UO	_	UO	21	HD	_	_
25	_	_	its	_	_	_	UO	_	UO	21	HD	_	_
26	_	_	scientific	_	_	_	UO	_	UO	21	AN	_	_
27	_	_	correctness	_	_	_	UO	_	UO	26	HD	_	_
28	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 59
# text =  III.
1	_	_	III	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
2	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 60
# text =  CONCLUSION The Council is invited to take note of this Progress Report and to instruct its preparatory bodies to, building on the general agreements already reached, pursue the examination of this proposal, in particular as concerns the various options for the " hospital exemption " (pt 13) and for the " combined products " (pt 10), with the aim of reaching swift agreement on the proposal.
1	_	_	CONCLUSION	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	8	SS	_	_
2	_	_	The	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	1	HD	_	_
3	_	_	Council	_	_	_	PM	ENAMEX.CRP.ORG	PM.NOM	1	HD	_	_
4	_	_	is	_	_	_	UO	_	UO	8	AA	_	_
5	_	_	invited	_	_	_	UO	_	UO	4	HD	_	_
6	_	_	to	_	_	_	UO	_	UO	4	HD	_	_
7	_	_	take	_	_	_	UO	_	UO	4	HD	_	_
8	_	_	note	_	_	_	VB	_	VB.PRT.AKT	0	ROOT	_	_
9	_	_	of	_	_	_	UO	_	UO	8	AA	_	_
10	_	_	this	_	_	_	UO	_	UO	9	HD	_	_
11	_	_	Progress	_	_	progress	NN	_	NN.UTR.SIN.IND.NOM	12	DT	_	_
12	_	_	Report	_	_	_	PM	_	PM.NOM	10	OO	_	_
13	_	_	and	_	_	_	UO	_	UO	12	ET	_	_
14	_	_	to	_	_	_	UO	_	UO	13	HD	_	_
15	_	_	instruct	_	_	_	UO	_	UO	13	HD	_	_
16	_	_	its	_	_	_	UO	_	UO	13	HD	_	_
17	_	_	preparatory	_	_	_	UO	_	UO	13	HD	_	_
18	_	_	bodies	_	_	_	UO	_	UO	13	HD	_	_
19	_	_	to	_	_	_	UO	_	UO	13	HD	_	_
20	_	_	,	_	_	_	MID	_	MID	13	IK	_	_
21	_	_	building	_	_	_	UO	ENAMEX.FNC.LOC	UO	13	AA	_	_
22	_	_	on	_	_	_	UO	_	UO	21	AN	_	_
23	_	_	the	_	_	_	UO	_	UO	22	HD	_	_
24	_	_	general	_	_	general	NN	_	NN.UTR.SIN.IND.NOM	23	SS	_	_
25	_	_	agreements	_	_	_	UO	_	UO	24	AN	_	_
26	_	_	already	_	_	_	UO	_	UO	25	HD	_	_
27	_	_	reached	_	_	_	UO	_	UO	26	HD	_	_
28	_	_	,	_	_	_	MID	_	MID	26	IK	_	_
29	_	_	pursue	_	_	_	UO	_	UO	26	AA	_	_
30	_	_	the	_	_	_	UO	_	UO	31	DT	_	_
31	_	_	examination	_	_	examination	NN	_	NN.UTR.SIN.IND.NOM	29	PA	_	_
32	_	_	of	_	_	_	UO	_	UO	31	ET	_	_
33	_	_	this	_	_	_	UO	_	UO	34	DT	_	_
34	_	_	proposal	_	_	proposal	NN	_	NN.UTR.SIN.IND.NOM	32	PA	_	_
35	_	_	,	_	_	_	MID	_	MID	34	IK	_	_
36	_	_	in	_	_	_	UO	_	UO	34	AN	_	_
37	_	_	particular	_	_	_	UO	_	UO	36	HD	_	_
38	_	_	as	_	_	_	UO	_	UO	39	DT	_	_
39	_	_	concerns	_	_	_	NN	_	NN.UTR.SIN.DEF.GEN	37	PA	_	_
40	_	_	the	_	_	_	UO	_	UO	39	ET	_	_
41	_	_	various	_	_	_	UO	_	UO	42	DT	_	_
42	_	_	options	_	_	option	NN	_	NN.UTR.SIN.IND.GEN	40	SS	_	_
43	_	_	for	_	_	_	UO	_	UO	34	ET	_	_
44	_	_	the	_	_	_	UO	_	UO	43	HD	_	_
45	_	_	"	_	_	_	PAD	_	PAD	43	IR	_	_
46	_	_	hospital	_	_	hospital	NN	_	NN.NEU.SIN.IND.NOM	47	DT	_	_
47	_	_	exemption	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	43	AN	_	_
48	_	_	"	_	_	_	PAD	_	PAD	47	JC	_	_
49	_	_	(	_	_	_	PAD	_	PAD	47	IR	_	_
50	_	_	pt	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	51	DT	_	_
51	_	_	13	_	_	_	RG	_	RG.NOM	47	AN	_	_
52	_	_	)	_	_	_	PAD	_	PAD	47	JR	_	_
53	_	_	and	_	_	_	UO	_	UO	47	AN	_	_
54	_	_	for	_	_	_	UO	_	UO	53	HD	_	_
55	_	_	the	_	_	_	UO	_	UO	54	HD	_	_
56	_	_	"	_	_	_	PAD	_	PAD	54	IR	_	_
57	_	_	combined	_	_	_	UO	_	UO	54	AN	_	_
58	_	_	products	_	_	_	UO	_	UO	57	HD	_	_
59	_	_	"	_	_	_	PAD	_	PAD	47	JR	_	_
60	_	_	(	_	_	_	PAD	_	PAD	43	IR	_	_
61	_	_	pt	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	62	DT	_	_
62	_	_	10	_	_	_	RG	_	RG.NOM	43	AN	_	_
63	_	_	)	_	_	_	PAD	_	PAD	62	JR	_	_
64	_	_	,	_	_	_	MID	_	MID	43	IK	_	_
65	_	_	with	_	_	_	UO	_	UO	71	DT	_	_
66	_	_	the	_	_	_	UO	_	UO	65	HD	_	_
67	_	_	aim	_	_	_	UO	_	UO	65	HD	_	_
68	_	_	of	_	_	_	UO	_	UO	65	HD	_	_
69	_	_	reaching	_	_	_	UO	_	UO	65	HD	_	_
70	_	_	swift	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	65	HD	_	_
71	_	_	agreement	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	74	DT	_	_
72	_	_	on	_	_	_	UO	_	UO	74	DT	_	_
73	_	_	the	_	_	_	UO	_	UO	74	DT	_	_
74	_	_	proposal	_	_	proposal	NN	_	NN.UTR.SIN.IND.NOM	42	AN	_	_
75	_	_	.	_	_	_	MAD	_	MAD	8	IP	_	_

# sent_id = 61
# text =  _ DS 338 / 06 ECO SAN CODEC.
1	_	_	_	_	_	_	RG	_	RG.NOM	2	TA	_	_
2	_	_	DS	_	_	_	VB	_	VB.PRT.SFO	0	ROOT	_	_
3	_	_	338	_	_	_	RG	_	RG.NOM	2	SP	_	_
4	_	_	/	_	_	_	MID	_	MID	3	IK	_	_
5	_	_	06	_	_	_	RG	_	RG.NOM	3	RA	_	_
6	_	_	ECO	_	_	_	PM	_	PM.NOM	5	ET	_	_
7	_	_	SAN	_	_	_	PM	ENAMEX.HUM.PRS	PM.NOM	6	HD	_	_
8	_	_	CODEC	_	_	_	PM	ENAMEX.HUM.PRS	PM.NOM	6	HD	_	_
9	_	_	.	_	_	_	MAD	_	MAD	2	IP	_	_

# sent_id = 62
# text =  DS 338 / 1 / 06 ECO SAN CODEC.
1	_	_	DS	_	_	_	PM	_	PM.NOM	0	ROOT	_	_
2	_	_	338	_	_	_	RG	_	RG.NOM	1	ET	_	_
3	_	_	/	_	_	_	MID	_	MID	4	IG	_	_
4	_	_	1	_	_	_	RG	_	RG.NOM	2	AN	_	_
5	_	_	/	_	_	_	MID	_	MID	4	ET	_	_
6	_	_	06	_	_	_	RG	_	RG.NOM	7	DT	_	_
7	_	_	ECO	_	_	_	PM	_	PM.NOM	5	ET	_	_
8	_	_	SAN	_	_	_	PM	ENAMEX.HUM.PRS	PM.NOM	7	HD	_	_
9	_	_	CODEC	_	_	_	PM	ENAMEX.HUM.PRS	PM.NOM	7	HD	_	_
10	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 63
# text =  Currently covered by Directive 2001 / 83 / EC.
1	_	_	Currently	_	_	_	PM	_	PM.NOM	2	SS	_	_
2	_	_	covered	_	_	_	VB	_	VB.PRT.AKT	0	ROOT	_	_
3	_	_	by	_	_	_	PM	_	PM.NOM	2	OO	_	_
4	_	_	Directive	_	_	_	PM	_	PM.NOM	3	HD	_	_
5	_	_	2001	_	_	_	RG	_	RG.NOM	2	OO	_	_
6	_	_	/	_	_	_	MID	_	MID	5	IK	_	_
7	_	_	83	_	_	_	RG	_	RG.NOM	8	CJ	_	_
8	_	_	/	_	_	_	MID	_	MID	5	ET	_	_
9	_	_	EC	_	_	_	PM	_	PM.NOM	8	CJ	_	_
10	_	_	.	_	_	_	MAD	_	MAD	2	IP	_	_

# sent_id = 64
# text =  Currently covered by Directive 2001 / 83 / EC.
1	_	_	Currently	_	_	_	PM	_	PM.NOM	2	SS	_	_
2	_	_	covered	_	_	_	VB	_	VB.PRT.AKT	0	ROOT	_	_
3	_	_	by	_	_	_	PM	_	PM.NOM	2	OO	_	_
4	_	_	Directive	_	_	_	PM	_	PM.NOM	3	HD	_	_
5	_	_	2001	_	_	_	RG	_	RG.NOM	2	OO	_	_
6	_	_	/	_	_	_	MID	_	MID	5	IK	_	_
7	_	_	83	_	_	_	RG	_	RG.NOM	8	CJ	_	_
8	_	_	/	_	_	_	MID	_	MID	5	ET	_	_
9	_	_	EC	_	_	_	PM	_	PM.NOM	8	CJ	_	_
10	_	_	.	_	_	_	MAD	_	MAD	2	IP	_	_

# sent_id = 65
# text =  Currently not covered by Community legislation.
1	_	_	Currently	_	_	_	PM	_	PM.NOM	0	ROOT	_	_
2	_	_	not	_	_	_	UO	_	UO	6	DT	_	_
3	_	_	covered	_	_	_	UO	_	UO	2	HD	_	_
4	_	_	by	_	_	_	UO	_	UO	2	HD	_	_
5	_	_	Community	_	_	_	PM	_	PM.NOM	6	DT	_	_
6	_	_	legislation	_	_	_	NN	_	NN.UTR.SIN.IND.NOM	1	TA	_	_
7	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 66
# text =  Annex I to Directive 2001 / 83 / EC.
1	_	_	Annex	_	_	_	NN	_	NN.NEU.SIN.IND.NOM	0	ROOT	_	_
2	_	_	I	_	_	i	PP	ENAMEX.HUM.PRS	PP	1	ET	_	_
3	_	_	to	_	_	_	PM	_	PM.NOM	2	PA	_	_
4	_	_	Directive	_	_	_	PM	_	PM.NOM	3	HD	_	_
5	_	_	2001	_	_	_	RG	_	RG.NOM	6	CJ	_	_
6	_	_	/	_	_	_	MID	_	MID	1	ET	_	_
7	_	_	83	_	_	_	RG	_	RG.NOM	8	CJ	_	_
8	_	_	/	_	_	_	MID	_	MID	6	ET	_	_
9	_	_	EC	_	_	_	PM	_	PM.NOM	8	CJ	_	_
10	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 67
# text =  OJ L311 28.11.2001 p.67-128.
1	_	_	OJ	_	_	_	IN	_	IN	0	ROOT	_	_
2	_	_	L311	_	_	_	PM	_	PM.NOM	1	ET	_	_
3	_	_	28.11.2001	_	_	_	RG	_	RG.NOM	2	ET	_	_
4	_	_	p.67-128	_	_	_	RG	_	RG.NOM	3	RA	_	_
5	_	_	.	_	_	_	MAD	_	MAD	1	IP	_	_

# sent_id = 68
# text =  9124 / 06 LES / ek DG C I LIMITE EN
1	_	_	9124	_	_	_	RG	_	RG.NOM	0	ROOT	_	_
2	_	_	/	_	_	_	MID	_	MID	1	IK	_	_
3	_	_	06	_	_	_	RG	_	RG.NOM	4	JG	_	_
4	_	_	LES	_	_	_	PM	_	PM.NOM	1	AN	_	_
5	_	_	/	_	_	_	MID	_	MID	4	IK	_	_
6	_	_	ek	_	_	_	JJ	_	JJ.AN	7	AT	_	_
7	_	_	DG	_	_	_	PM	_	PM.NOM	4	ET	_	_
8	_	_	C	_	_	_	PM	_	PM.NOM	7	HD	_	_
9	_	_	I	_	_	i	PP	_	PP	7	ET	_	_
10	_	_	LIMITE	_	_	_	PM	_	PM.NOM	9	PA	_	_
11	_	_	EN	_	_	4	DT.UTR.SIN.IND	4	en	DT	ROOT	_	_

